Document:

EX-10.12

 Exhibit 10.12 

*Portions of this exhibit have been excluded because it both (i) is not material and (ii)

would be competitively harmful if publicly disclosed. 

CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT 

by and among 
 MSD
International GmbH, 
 MSD International Business GmbH, 

and 
 IO Biotech ApS

 TABLE OF CONTENTS 

									
		  		  	 	Page	 
			
	1.	  	Definitions	  	 	1	 
			
	2.	  	Scope of the Agreement	  	 	9	 
				
		  	2.1	  	Generally	  	 	9	 
		  	2.2	  	Manufacturing Delay	  	 	9	 
		  	2.3	  	Compound Commitments	  	 	9	 
		  	2.4	  	Delegation of Obligations	  	 	10	 
		  	2.5	  	Compounds	  	 	10	 
			
	3.	  	Conduct of the Study	  	 	10	 
				
		  	3.1	  	Sponsor	  	 	10	 
		  	3.2	  	Performance	  	 	10	 
		  	3.3	  	Debarred Personnel; Exclusions Lists	  	 	10	 
		  	3.4	  	Regulatory Matters	  	 	10	 
		  	3.5	  	Documentation	  	 	11	 
		  	3.6	  	Copies and Data Protection	  	 	11	 
		  	3.7	  	Sample Testing	  	 	11	 
		  	3.8	  	Ownership and Use of Clinical Data	  	 	11	 
		  	3.9	  	Joint Development Committee; Alliance Managers	  	 	12	 
		  	3.10	  	Interim Analysis	  	 	13	 
		  	3.11	  	Final Analysis	  	 	13	 
		  	3.12	  	Regulatory Agreement	  	 	13	 
		  	3.13	  	Relationship	  	 	13	 
		  	3.14	  	Licensing	  	 	14	 
			
	4.	  	Protocol, Statistical Analysis Plan and Informed Consent; Certain Covenants	  	 	14	 
				
		  	4.1	  	Protocol and Statistical Analysis Plan	  	 	14	 
		  	4.2	  	Informed Consent	  	 	14	 
		  	4.3	  	Financial Disclosure	  	 	14	 
		  	4.4	  	Transparency Reporting	  	 	15	 
			
	5.	  	Adverse Event Reporting	  	 	15	 
				
		  	5.1	  	Pharmacovigilance Agreement	  	 	15	 
		  	5.2	  	Transmission of SAEs	  	 	16	 
			
	6.	  	Term and Termination	  	 	16	 
				
		  	6.1	  	Term	  	 	16	 
		  	6.2	  	Termination for Material Breach	  	 	16	 
		  	6.3	  	Termination for Patient Safety	  	 	16	 
		  	6.4	  	Termination for Regulatory Action; Other Reasons	  	 	17	 
		  	6.5	  	Termination Related to Anti-Corruption Obligations	  	 	17	 
		  	6.6	  	Return of MSD Compound	  	 	17	 
		  	6.7	  	Survival	  	 	17	 
		  	6.8	  	No Prejudice	  	 	17	 
		  	6.9	  	Confidential Information	  	 	17	 
		  	6.10	  	Manufacturing Costs	  	 	18	 

  
 

 

 Confidential 
  

													
			
	7.	  	Costs of Study	 	  	 	18	 
			
	8.	  	Supply and Use of the Compounds	 	  	 	18	 
				
		  	8.1	  	Supply of the Compounds	  
	  	 	18	 
		  	8.2	  	Clinical Quality Agreement	  
	  	 	18	 
		  	8.3	  	Minimum Shelf Life Requirements	  
	  	 	18	 
		  	8.4	  	Provision of Compounds	  
	  	 	18	 
		  	8.5	  	Labeling and Packaging; Use, Handling and Storage	  
	  	 	19	 
		  	8.6	  	Product Specifications	  
	  	 	19	 
		  	8.7	  	Changes to Manufacturing	  
	  	 	19	 
		  	8.8	  	Product Testing; Noncompliance	  
	  	 	20	 
		  	8.9	  	Investigations	  
	  	 	21	 
		  	8.10	  	Shortage; Allocation	  
	  	 	21	 
		  	8.11	  	Records; Audit Rights	  
	  	 	21	 
		  	8.12	  	Quality	  
	  	 	21	 
		  	8.13	  	Quality Control	  
	  	 	21	 
		  	8.14	  	Audits and Inspections	  
	  	 	21	 
		  	8.15	  	 Recalls

VAT
	  

 
	  	 	21	 
		  	8.16	  	 	22	 
			
	9.	  	Confidentiality	 	  	 	22	 
				
		  	9.1	  	Confidential Information	  
	  	 	22	 
		  	9.2	  	Inventions	  
	  	 	23	 
		  	9.3	  	Personal Identifiable Data	  
	  	 	23	 
			
	10.	  	Intellectual Property	 	  	 	23	 
				
		  	10.1	  	Joint Ownership and Prosecution	  
	  	 	23	 
		  	10.2	  	Inventions Owned by Company	  
	  	 	24	 
		  	10.3	  	Inventions Owned by MSD	  
	  	 	24	 
		  	10.4	  	Mutual Freedom to Operate for Combination Inventions	  
	  	 	24	 
		  	10.5	  	Right of First Negotiation	  
	  	 	24	 
			
	11.	  	Reprints; References in Publication	 	  	 	25	 
			
	12.	  	Publications; Press Releases	 	  	 	25	 
				
		  	12.1	  	Clinical Trial Registry	  
	  	 	25	 
		  	12.2	  	Publication	  
	  	 	25	 
		  	12.3	  	Press Releases	  
	  	 	26	 
			
	13.	  	Representations and Warranties; Disclaimers	 	  	 	26	 
				
		  	13.1	  	Due Authorization	  
	  	 	26	 
		  	13.2	  	Compounds	  
	  	 	26	 
		  	13.3	  	Results	  				  	 	26	 
		  	13.4	  	Anti-Corruption	  
	  	 	27	 
		  	13.5	  	DISCLAIMER	  
	  	 	28	 

  
 ii 

 Confidential 
  

									
			
	14.	  	Insurance; Indemnification; Limitation of Liability	  	 	29	 
				
		  	14.1	  	Insurance	  	 	29	 
		  	14.2	  	Indemnification	  	 	29	 
		  	14.3	  	LIMITATION OF LIABILITY	  	 	29	 
			
	15.	  	Use of Name	  	 	30	 
			
	16.	  	Force Majeure	  	 	30	 
			
	17.	  	Entire Agreement; Amendment; Waiver	  	 	30	 
			
	18.	  	Assignment and Affiliates	  	 	31	 
			
	19.	  	Change of Control	  	 	31	 
			
	20.	  	Invalid Provision	  	 	31	 
			
	21.	  	No Additional Obligations	  	 	32	 
			
	22.	  	Governing Law; Dispute Resolution	  	 	32	 
			
	23.	  	Notices	  	 	33	 
			
	24.	  	Relationship of the Parties	  	 	33	 
			
	25.	  	Counterparts and Due Execution	  	 	33	 
			
	26.	  	Construction	  	 	34	 

 Appendices 
 Appendix A
– Protocol 
 Appendix B – Supply of Compound 

Appendix C – Data Protection Terms 
 Appendix D – Form
of Press Release 
 Schedules 
 Schedule I – Data
Sharing Schedule 
 Schedule II – Sample Testing Schedule 

  
 iii 

 Confidential 
  

 CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT 

This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), is entered into as of the date of last signature
hereunder (the “Effective Date”), by and among MSD International GmbH (“MSDIG”), MSD International Business GmbH (“MSDIB” and collectively with MSDIG, “MSD”), having a place of business at [***] and IO Biotech
ApS, having a place of business at [***] (“Company”). MSD and Company are each referred to herein individually as “Party” and collectively as “Parties”. 

RECITALS 
  

	A.	 MSD and/or its Affiliates holds intellectual property rights with respect to the MSD Compound (as defined
below). 

  

	B.	 Company is developing the Company Compounds (as defined below) for the treatment of certain tumor types.

  

	C.	 MSD and/or its Affiliates is developing the MSD Compound for the treatment of certain tumor types.

  

	D.	 Company desires to sponsor a clinical trial in which the Company Compounds and the MSD Compound would be dosed
concurrently or in combination. 

  

	E.	 MSD and Company, consistent with the terms of this Agreement, desire to collaborate as more fully described
herein, including by providing the MSD Compound and the Company Compounds for the Study (as defined below). 

 NOW,
THEREFORE, in consideration of the premises and of the following mutual promises, covenants and conditions, the Parties, intending to be legally bound, mutually agree as follows: 

 

	1.	 Definitions. 

For all purposes of this Agreement, the capitalized terms defined in this Article 1 and throughout this Agreement shall have the
meanings herein specified. 
 1.1 “Affiliate” means, with respect to either Party, a person, firm, corporation, partnership
or other entity that, now or hereafter, directly or indirectly owns or controls said Party, or, now or hereafter, is owned or controlled by said Party, or is under common ownership or control with said Party. The word “control” as
used in this definition means (a) the direct or indirect ownership of fifty percent (50%) or more of the outstanding voting securities of a legal entity or (b) possession, directly or indirectly, of the power to direct the management or
policies of a legal entity, whether through the ownership of voting securities, contract rights, voting rights, corporate governance or otherwise. 

1.2 “Agreement” means this agreement, as amended by the Parties from time to time, and as set forth in the preamble. 

 Confidential 
  

 1.3 “Alliance Manager” has the meaning set forth in
Section 3.9.3. 
 1.4 “Applicable Law” means all federal, state, local, national and regional
statutes, laws, rules, regulations and directives applicable to a particular activity hereunder, including performance of clinical trials, medical treatment and the processing and protection of personal and medical data, that may be in effect from
time to time, including those promulgated by the United States Food and Drug Administration (“FDA”), national regulatory authorities, the European Medicines Agency (“EMA”) and any successor agency to the FDA or EMA or any agency
or authority performing some or all of the functions of the FDA or EMA in any jurisdiction outside the United States or the European Union (each a “Regulatory Authority” and collectively, “Regulatory Authorities”), and including
cGMP and GCP (each as defined below); Data Protection Laws; export control and economic sanctions regulations which prohibit the shipment of United States-origin products and technology to certain restricted countries, entities and individuals;
anti-bribery and anti-corruption laws pertaining to interactions with government agents, officials and representatives; laws and regulations governing payments to healthcare providers; and any United States or other country’s or
jurisdiction’s successor or replacement statutes, laws, rules, regulations and directives relating to the foregoing. 
 1.5
“Business Day” means any day other than a Saturday, Sunday, or a day on which commercial banks located in the country where the applicable obligations are to be performed are authorized or required by law to be closed. 

1.6 “cGMP” means the current Good Manufacturing Practices officially published and interpreted by EMA, FDA and other
applicable Regulatory Authorities that may be in effect from time to time and are applicable to the Manufacture of the Compounds. 
 1.7
“Change of Control” means, with respect to the Company, and except for any change resulting solely from change in the legal domicile of the Company and/or its Affiliates (e.g. from ApS to US
C-Corp entity) , (a) the sale of all or substantially all of the assets or business relating to this Agreement; or (b) a merger, reorganization or consolidation involving the Company in which the
voting securities immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization or consolidation; (c) any Third Party (or group
of Third Parties acting in concert) becoming the beneficial owner directly or indirectly, of fifty percent (50%) or more of the total voting power of the Company; or (d) the acquisition by a Third Party of the right to nominate a
majority of the members of the board of directors (or similar governing body), or to otherwise control the affairs of the Company. 
 1.8
“Clinical Data” means all data (including raw data) and results generated by or on behalf of either Party or at either Party’s direction, or by or on behalf of the Parties together or at their direction, in the course of each
such Party’s performance of the Study, [***]. For clarity, Clinical Data shall include Personal Data collected for the Study which is necessary or useful by a Party: (a) for the interpretation or analysis of Study results; (b) for the
development of Compounds in accordance with this Agreement; (c) for any submission or response to a Regulatory Authority; (d) to comply with Applicable Law; or (e) to conduct any activities in accordance with this Agreement. 

  
 2 

 Confidential 
  

 1.9 [***] 

1.10 “Clinical Quality Agreement” has the meaning set forth in Section 8.2. 

1.11 “CMC” means “Chemistry Manufacturing and Controls” as such term of art is used in the pharmaceutical
industry. 
 1.12 “Combination” means the use or method of using both Company Compounds and the MSD Compound [***]. 

1.13 “Combination Data” has the meaning set forth in Section 3.8.1. 

1.14 “Company” has the meaning set forth in the preamble. 

1.15 “Company Background Patents” has the meaning set forth in Section 10.4.1. 

1.16 “Company Class Compound” means [***]. 

1.17 “Company Compounds” means the compounds designated as IO102 and IO103 respectively, [***]. A “Company
Compound” means either IO102 or IO103, as applicable. 
 1.18 “Company Inventions” has the meaning set forth in
Section 10.2. 
 1.19 “Compounds” means the Company Compounds and the MSD Compound. A
“Compound” means either of the Company Compounds or the MSD Compound, as applicable. 
 1.20 “Confidential
Information” means any information, Know-How or other proprietary information or materials furnished to one Party (“Receiving Party”) by or on behalf of the other Party
(“Disclosing Party”) in connection with this Agreement, including all Personal Data subject to Data Protection Laws, except to the extent that such information or materials: (a) was already known to the Receiving Party, other
than under an obligation of confidentiality, at the time of disclosure by the Disclosing Party, [***]; (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party;
(c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the Receiving Party in breach of this Agreement; (d) was disclosed to the Receiving
Party by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others; or (e) was subsequently developed by the Receiving Party without use of the Disclosing Party Confidential Information, [***]. 

1.21 “Continuing Party” has the meaning set forth in Section 10.1.3. 

1.22 “Control” or “Controlled” means, with respect to particular information or intellectual property, that
the applicable Party owns or has a license to such information or intellectual property and has the ability to grant a right, license or sublicense to the other Party as provided for herein [***]. 

1.23 “CTA” means an application to a Regulatory Authority for purposes of requesting the ability to start or continue a
clinical trial. 

  
 3 

 Confidential 
  

 1.24 “Data Protection Terms” means Appendix C hereto, which ensures
certain protections are in place for the processing personal data in the performance of the Study and sets forth the Parties’ responsibilities for certain obligations, including addressing the rights of data subjects, ensuring a legal basis for
processing personal data, conducting appropriate data-protection impact assessments and prior consultations with relevant supervisory authorities, complying with all personal-data breach-notification obligations, and certain other compliance
obligations under Data Protection Law. 
 1.25 “Data Protection Law” has the meaning set forth in the Data Protection
Terms. 
 1.26 “Data Sharing Schedule” means the schedule attached hereto as Schedule I. 

1.27 “Defending Party” has the meaning set forth in Section 14.2.3. 

1.28 “Delivery” with respect to the MSD Compound has the meaning set forth in Section 8.4.1, and
with respect to the Company Compounds, the meaning set forth in Section 8.4.2. 
 1.29 [***] 

1.30 “Disclosing Party” has the meaning set forth in the definition of Confidential Information. 

1.31 “Disposition Package” has the meaning set forth in Section 8.8.1. 

1.32 “Effective Date” has the meaning set forth in the preamble. 

1.33 “EMA” has the meaning set forth in the definition of Applicable Law. 

1.34 “Exclusions List” has the meaning set forth in the definition of Violation. 

1.35 “FDA” has the meaning set forth in the definition of Applicable Law. 

1.36 “Filing Party” has the meaning set forth in Section 10.1.3. 

1.37 “Final Analysis” has the meaning set forth in Section 3.11. 

1.38 “First Party” has the meaning set forth in Section 8.16.2. 

1.39 “Force Majeure” has the meaning set forth Article 16. 

1.40 “GAAP” has the meaning set forth in Section 6.10. 

1.41 “GCP” means the Good Clinical Practices officially published by EMA, FDA and the International Conference on
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) that may be in effect from time to time and are applicable to the testing of the Compounds. 

  
 4 

 Confidential 
  

 1.42 “Government Official” means: (a) any officer or employee of a
government or any department, agency or instrument of a government; (b) any Person acting in an official capacity for or on behalf of a government or any department, agency, or instrument of a government; (c) any officer or employee of a
company or business owned in whole or part by a government; (d) any officer or employee of a public international organization such as the World Bank or United Nations; (e) any officer or employee of a political party or any Person acting
in an official capacity on behalf of a political party; and/or (f) any candidate for political office; who, when such Government Official is acting in an official capacity, or in an official decision-making role, has responsibility for
performing regulatory inspections, government authorizations or licenses, or otherwise has the capacity to make decisions with the potential to affect the business of either of the Parties. 

1.43 “IND” means any Investigational New Drug Application filed or to be filed with the FDA as described in Title 21 of
the U.S. Code of Federal Regulations, Part 312, and the equivalent application in the jurisdictions outside the United States, including an “Investigational Medicinal Product Dossier” filed or to be filed with Regulatory Authorities
in the European Union. 
 1.44 [***] 

1.45 “Interim Analysis” has the meaning set forth in Section 3.10. 

1.46 “Inventions” means all inventions and discoveries, whether or not patentable, that are made, conceived, or first
actually reduced to practice by or on behalf of a Party, or by or on behalf of the Parties together, [***]. 
 1.47 “Joint
Development Committee” or “JDC” has the meaning set forth in Section 3.9.1. 
 1.48
“Joint Patent Application” has the meaning set forth in Section 10.1.3. 
 1.49 “Joint
Patent” means a patent, extension, registration, supplementary protection certificate or the like that issues from a Joint Patent Application. 

1.50 “Jointly Owned Invention” has the meaning set forth in Section 10.1.1. 

1.51 “Know-How” means any proprietary invention, innovation, improvement,
development, discovery, computer program, device, trade secret, method, know-how, process, technique or the like, including manufacturing, use, process, structural, operational and other data and information,
whether or not written or otherwise fixed in any form or medium, regardless of the media on which contained and whether or not patentable or copyrightable, that is not generally known or otherwise in the public domain. 

1.52 “Liability” has the meaning set forth in Section 14.2.1. 

1.53 “Manufacture,” “Manufactured,” or “Manufacturing” means all activities related to the
manufacture of a Compound, including planning, purchasing, manufacture, processing, compounding, storage, filling, packaging, waste disposal, labeling, leafleting, testing, quality assurance, sample retention, stability testing, release, dispatch
and supply, as applicable. 

  
 5 

 Confidential 
  

 1.54 “Manufacturer’s Release” or “Release” has the
meaning ascribed to such term in the Clinical Quality Agreement. 
 1.55 “Manufacturing Site” means the facilities where a
Compound is Manufactured by or on behalf of a Party, as such Manufacturing Site may change from time to time in accordance with Section 8.7. 

1.56 “MSD” has the meaning set forth in the preamble. 

1.57 “MSD Background Patents” has the meaning set forth in Section 10.4.2. 

1.58 “MSD Compound” means pembrolizumab, a humanized anti-human PD-1 monoclonal
antibody, [***]. 
 1.59 “MSDIB” has the meaning set forth in the preamble. 

1.60 “MSDIG” has the meaning set forth in the preamble. 

1.61 “MSD Inventions” has the meaning set forth in Section 10.3. 

1.62 “MSD Right” has the meaning set forth in Section 10.5.2. 

1.63 “NDA” means a New Drug Application, Biologics License Application, Marketing Authorization Application, filing pursuant
to Section 510(k) of the United States Federal Food, Drug and Cosmetic Act, or similar application or submission for a marketing authorization of a product filed with a Regulatory Authority to obtain marketing approval for a biological,
pharmaceutical or diagnostic product in that country or in that group of countries. 
 1.64 “Negotiation Period” has the
meaning set forth in Section 10.5.2. 
 1.65
“Non-Conformance” means, with respect to a given unit of Compound, (a) an event that deviates from an approved cGMP requirement with respect to the applicable Compound, such as a
procedure, Specification, or operating parameter, or that requires an investigation to assess impact to the quality of the applicable Compound or (b) that such Compound failed to meet the applicable representations and warranties set forth in
Section 2.3. Classification of the Non-Conformance is detailed in the Clinical Quality Agreement. 

1.66 “Non-Filing Party” has the meaning set forth in
Section 10.1.3. 
 1.67 “Opting-out Party” has the
meaning set forth in Section 10.1.3. 
 1.68 “Other Party” has the meaning set forth in
Section 14.2.3. 
 1.69 “Party” or “Parties” has the meaning set forth in the
preamble. 
 1.70 “PD-1 Antagonist” means any [***]. 

1.71 “Pembro-Only Arm” shall mean the arm of the Study involving the MSD Compound only and not the Company Compounds. 

  
 6 

 Confidential 
  

 1.72 “Pembro-Only Arm Data” shall mean all data (including raw data)
generated under the Pembro-Only Arm. 
 1.73 “Person” means any individual, sole proprietorship, partnership, corporation,
business trust, joint stock company, trust, unincorporated organization, association, limited liability company, institution, public benefit corporation, joint venture, entity or governmental entity. 

1.74 “Personal Data” has the meaning set forth for “personal data” in the European Commission Decision
2004/915/EC, as amended. 
 1.75 “Pharmacovigilance Agreement” has the meaning set forth in
Section 5.1. 
 1.76 “Prior CDA” has the meaning set forth in Article 17. 

1.77 “Project Manager” has the meaning set forth in Section 3.9.1. 

1.78 “Protocol” means the written documentation set forth in Appendix A that describes the Study
and sets forth specific activities to be performed as part of the conduct of the Study. 
 1.79 “Receiving Party” has the
meaning set forth in the definition of Confidential Information. 
 1.80 “Regulatory Agreement” means that certain
regulatory agreement regarding the Compounds to be entered into by the Parties pursuant to Section 3.12, as the same may be amended from time to time. 

1.81 “Regulatory Approvals” means, with respect to a Compound, any and all permissions (other than the Manufacturing
approvals) required to be obtained from Regulatory Authorities and any other competent authority for the development, registration, importation, use, distribution, sale and marketing of such Compound in the United States, Europe or other applicable
jurisdictions, including any pricing or reimbursement approvals. 
 1.82 “Regulatory Authority” or “Regulatory
Authorities” has the meaning set forth in the definition of Applicable Law. 
 1.83 “Regulatory Documentation”
means, with respect to the Compounds, all submissions to Regulatory Authorities in connection with the development of such Compounds, including all INDs and amendments thereto, CTAs, NDAs and amendments thereto, drug master files including CMC data,
correspondence with regulatory agencies, periodic safety update reports, adverse event files, complaint files, inspection reports and manufacturing records, in each case, together with all supporting documents (including documents that include
Clinical Data). 
 1.84 “Related Agreements” means the Pharmacovigilance Agreement, the Clinical Quality Agreement, and the
Regulatory Agreement. 

  
 7 

 Confidential 
  

 1.85 “Right of Reference” means the “right of reference” defined
in 21 CFR 314.3(b), including with regard to a Party, allowing the applicable Regulatory Authority in a country to have access to relevant information (by cross-reference, incorporation by reference or otherwise) contained in Regulatory
Documentation (and any data contained therein) filed with such Regulatory Authority with respect to a Party’s Compound(s), only to the extent necessary for the other Party to conduct the Study in such country or as otherwise expressly permitted
or required under this Agreement to enable the other Party to exercise its rights or perform its obligations hereunder. 
 1.86
“ROFN Period” has the meaning set forth in Section 10.5.1. 
 1.87 “ROFN
Transaction” has the meaning set forth in Section 10.5.1. 
 1.88 “SAEs” has the meaning
set forth in Section 5.2. 
 1.89 “Samples” means biological specimens collected from subjects
participating in the Study, including urine, blood and tissue samples. 
 1.90 “Sample Testing” means the analyses to be
performed by each Party using the applicable Samples, as described in the Sample Testing Schedule. 
 1.91 “Sample Testing
Results” means those data and results arising from the Sample Testing performed by a Party. 
 1.92 “Sample Testing
Schedule” means the schedule attached hereto as Schedule II. 
 1.93 “Second Party” has
the meaning set forth in Section 8.16.2. 
 1.94 “Sensitive Information” means unpublished Pembro-Only Arm Data,
Sample Testing Results generated by MSD and Confidential Information relating to MSD Inventions or the MSD Compound (but not information solely relating to a Company Compound and not to the MSD Compound). 

1.95 “Special Categories of Data” has the meaning set forth for “special categories of data” in the European
Commission Decision 2004/915/EC, as amended. 
 1.96 “Specifications” means, with respect to a given Compound, the set of
requirements for such Compound as set forth in the Clinical Quality Agreement. 
 1.97 “Study” means the study titled
“Randomized Phase II/III trial of IO102-IO103 plus pembrolizumab versus pembrolizumab in anti PD-1 naïve advanced melanoma” as described in the Protocol. 

1.98 “Study Completion” has the meaning set forth in Section 3.11. 

1.99 “Subcontractors” has the meaning set forth in Section 2.4. 

1.100 “Term” has the meaning set forth in Section 6.1. 

1.101 “Third Party” means any Person or entity other than Company, MSD or their respective Affiliates. 

  
 8 

 Confidential 
  

 1.102 “Toxicity and Safety Data” means all clinical adverse
event information and/or patient-related safety data [***] 
 1.103 “Transparency Report” has the meaning set forth in
Section 4.4. 
 1.104 “Unsolicited Offer” has the meaning set forth in
Section 10.5.1. 
 1.105 “VAT” has the meaning set forth in
Section 8.16. 
 1.106 “Violation” means that a Party or any of its officers or directors or any
other personnel (or other permitted agents of a Party performing activities hereunder) has been: (a) convicted of any of the felonies identified among the exclusion authorities listed on the U.S. Department of Health and Human Services, Office
of Inspector General (OIG) website, including 42 U.S.C. 1320a-7(a) (http://oig.hhs.gov/exclusions/authorities.asp); (b) identified in the OIG List of Excluded Individuals/Entities (LEIE) database
(http://exclusions.oig.hhs.gov/) or listed as having an active exclusion in the System for Award Management (http://www.sam.gov); or (c) listed by any US Federal agency as being suspended, proposed for debarment, debarred, excluded or otherwise
ineligible to participate in Federal procurement or non-procurement programs, including under 21 U.S.C. 335a (http://www.fda.gov/ora/compliance_ref/debar/) ((a), (b) and (c) collectively the
“Exclusions Lists”). 
  

	2.	 Scope of the Agreement. 

2.1 Generally. Each Party shall: (a) contribute to the Study such resources as are necessary to fulfill its obligations set forth
in this Agreement; and (b) act in good faith in performing its obligations under this Agreement and each Related Agreement to which it is a Party. 

2.2 Manufacturing Delay. Each Party shall notify the other Party as promptly as possible in the event of any Manufacturing delay
that is likely to adversely affect supply of its Compound(s) as contemplated by this Agreement. 
 2.3 Compound Commitments. 

2.3.1 Company agrees to Manufacture and supply the Company Compounds for purposes of the Study in accordance with
Article 8, and Company hereby represents and warrants to MSD that, at the time of Delivery of the Company Compounds, such Company Compounds shall have been Manufactured and supplied in compliance with: (a) the
Specifications for the Company Compounds; (b) the Clinical Quality Agreement; and (c) all Applicable Law, including cGMP and health, safety and environmental protections. 

2.3.2 MSD and/or its Affiliate(s) agrees to Manufacture and supply the MSD Compound for purposes of the Study in accordance with
Article 8, and MSD and/or its Affiliate(s) hereby represents and warrants to Company that, at the time of Delivery of the MSD Compound, such MSD Compound shall have been Manufactured and supplied in compliance with:
(a) the Specifications for the MSD Compound; (b) the Clinical Quality Agreement; and (c) all Applicable Law, including cGMP and health, safety and environmental protections. 

  
 9 

 Confidential 
  

 2.3.3 Without limiting the foregoing, each Party is responsible for obtaining all regulatory
approvals (including facility licenses) that are required to Manufacture its Compound(s) in accordance with Applicable Law (provided that, for clarity, Company shall be responsible for obtaining Regulatory Approvals for the Study as set forth in
Section 3.4). 
 2.4 Delegation of Obligations. Each Party shall have the right
to delegate any portion of its obligations hereunder as follows: (a) to such Party’s Affiliates; (b) to Third Parties that are set forth on Schedule 2.4 or are set forth in the Protocol as performing Study activities or as
conducting Sample Testing for such Party; (c) to Third Parties solely in connection with the Manufacture of such Party’s Compound(s); and (d) upon the other Party’s prior written consent. Any and all Third Parties to whom a Party
delegates any of its obligations hereunder are referred to as “Subcontractors”. Notwithstanding any delegation of its obligations hereunder, each Party shall remain solely and fully liable for the performance of its Affiliates and
Subcontractors to which such Party delegates the performance of its obligations under this Agreement. Each Party shall ensure that each of its Affiliates and Subcontractors performs such Party’s obligations pursuant to the terms of this
Agreement, including the Appendices and Schedules attached hereto. Each Party shall use reasonable efforts to obtain and maintain copies of documents relating to the obligations performed by such Affiliates and Subcontractors that are required to be
provided to the other Party under this Agreement. 
 2.5 Compounds. This Agreement does not create any
obligation on the part of MSD and/or its Affiliate(s) to provide the MSD Compound for any activities other than the Study, nor does it create any obligation on the part of Company to provide the Company Compounds for any activities other than the
Study. 
  

	3.	 Conduct of the Study. 

3.1 Sponsor. Company shall act as the sponsor of the Study under an approved IND or CTA for the Company
Compounds with a Right of Reference to the IND or CTA of the MSD Compound, as necessary, as further described in Section 3.4; provided, however, that in no event shall Company file an additional IND or CTA for the Study
unless required by Regulatory Authorities to do so. If a Regulatory Authority requests an additional IND or CTA for the Study, the Parties shall meet and mutually agree on an approach to address such requirement. 

3.2 Performance. Company shall ensure that the Study is performed in accordance with this Agreement, the
Protocol and all Applicable Law, including GCP. 
 3.3 Debarred Personnel; Exclusions Lists. [***] 

3.4 Regulatory Matters. Company shall: (a) obtain, prior to initiating the Study, all Regulatory Approvals from all Regulatory
Authorities, ethics committees and/or institutional review boards with jurisdiction over the Study prior to initiating the Study; and (b) follow all directions from any such Regulatory Authorities, ethics committees and/or institutional review
boards. MSD [***] with a Regulatory Authority regarding matters related to the MSD Compound. MSD shall authorize FDA and other applicable Regulatory Authorities to cross-reference the appropriate MSD Compound INDs and CTAs to provide data access and
a Right of Reference to Company solely to the extent needed to enable Company to fulfil its obligations in connection with 

  
 10 

 Confidential 
  

 
Company’s conduct of the Study. If MSD’s CTA is not available in a given country, [***]. If a Right of Reference to Company’s INDs or CTAs for the Company Compounds is necessary
for MSD to fulfill its obligations in connection with the conduct of the Study, Company shall provide a cross-reference letter or similar communication to the applicable Regulatory Authority if needed to effectuate the Right of Reference solely to
the extent needed to enable MSD to fulfill its obligations in connection with the conduct of the Study. [***] 
 3.5 Documentation .
Company shall maintain reports and all related documentation in good scientific manner and in compliance with Applicable Law. Company shall provide to MSD all Study information and documentation reasonably requested by MSD to enable MSD to
(a) comply with any of its legal, regulatory and/or Third Party contractual obligations, or any request by any Regulatory Authority, related to the MSD Compound and (b) determine whether the Study has been performed in accordance with this
Agreement. 
 3.6 Copies and Data Protection . Company shall provide to MSD copies of all Clinical Data, in electronic
form or other mutually agreeable alternate form on the timelines specified in the Data Sharing Schedule (if applicable) or upon mutually agreeable timelines; provided, however, that a complete copy of the Clinical Data shall be provided to MSD no
later than [***] following Study Completion. Company shall ensure that all patient authorizations and consents required under Data Protection Laws in connection with the Study permit such sharing of Clinical Data with MSD, and each Party shall
ensure that it complies with Applicable Law in transferring personal data in connection with sharing the Clinical Data. The Parties will comply with the Data Protection Terms set forth in Appendix C, which are incorporated into and form a part of
this Agreement. In the event of any inconsistencies between the Data Protection Terms and the other terms of this Agreement, the Data Protection Terms will control as set forth in the Data Protection Terms. 

3.7 Sample Testing . 

3.7.1 Company shall provide Samples to MSD as specified in the Protocol or as agreed to by the Joint Development Committee. Each Party shall
(a) use the Samples only for the Sample Testing and (b) conduct the Sample Testing solely in accordance with the Sample Testing Schedule and the Protocol. 

3.7.2 [***] 
 3.7.3 [***] 

3.7.4 Except to the extent otherwise agreed in a writing signed by authorized representatives of each Party, each Party may use and disclose
the Sample Testing Results owned by the other Party and shared by such other Party in accordance with the Sample Testing Schedule [***]. 

3.8 Ownership and Use of Clinical Data . 

3.8.1 All Clinical Data other than Pembro Only Arm Data (the “Combination Data”) shall be jointly owned by Company and MSD. [***]
Company shall maintain the Clinical Data in its internal database; provided, however, that at all times during the Term, Company shall grant MSD access to all Clinical Data for uses permitted in this Agreement. [***]. 

  
 11 

 Confidential 
  

 3.8.2 Notwithstanding the foregoing Section 3.8.1, before
publication of the Combination Data in accordance with Article 12: [***]; provided, however, that the foregoing shall not limit or restrict either Party’s ability to [***]. If a Party believes disclosure of Clinical
Data is necessary to comply with Applicable Law or rules of a securities exchange, such Party shall promptly inform the other Party of the disclosure that is being sought, and consult and cooperate fully with the other Party in order to provide the
other Party an opportunity to challenge or limit the disclosure obligations. Any information disclosed shall remain otherwise subject to the confidentiality and non-use provisions of this Section, and the
Party disclosing such information shall take all steps reasonably necessary, including without limitation obtaining an order of confidentiality, to ensure the continued confidential treatment of such information. 

3.8.3 Notwithstanding anything to the contrary in this Section 3.8, unpublished Clinical Data from the Study may be
used [***]. If MSD desires to update its label for the MSD Compound to add an indication involving administration of the MSD Compound in a Combination or if Company desires to seek Regulatory Approval of a Company Compound for an indication
involving administration of the Company Compound in a Combination, in each case, based on the results of the Study, such Party shall notify the other Party at least [***] prior to submitting any Regulatory Documentation to initiate such label change
or obtain such Regulatory Approval. [***] 
 3.8.4 Notwithstanding anything to the contrary in this Section 3.8,
Company may: [***]; and (iii) Company must notify MSD at least [***] before such disclosure of the reasons for the planned disclosure [***] before such disclosure of the reasons for the planned disclosure and provide MSD with a copy of the
Combination Data and topline results of the Pembro-Only Arm and any related summaries or analyses, as applicable, which are to be disclosed, and further provided that with respect to topline results of the Pembro-Only Arm only, Company shall
consider in good faith and implement MSD’s comments to the extent consistent with such Applicable Law, applicable securities laws and applicable rules of such securities exchange. 

3.9 Joint Development Committee; Alliance Managers . 

3.9.1 As soon as practicable after the Effective Date, the Parties shall form a joint development committee (the “Joint Development
Committee” or “JDC”) made up of an equal number of representatives of MSD and Company, which shall have responsibility for coordinating all regulatory and other activities under, and pursuant to, this Agreement. The JDC
will review and finalize the Protocol in accordance with Section 4.1. Each Party shall designate a project manager (the “Project Manager”) who shall be responsible for implementing and coordinating
activities and facilitating the exchange of information between the Parties with respect to the Study and shall be a member of the JDC. Other JDC members will be agreed by both Parties. 

  
 12 

 Confidential 
  

 3.9.2 The JDC shall meet as soon as practicable after its formation and then no less than
[***], and more often as reasonably considered necessary at the request of either Party, to provide an update on the progress of the Study. The JDC may meet in person or by means of teleconference, internet conference, videoconference or other
similar communications equipment. Prior to any such meeting, Company’s Project Manager shall provide an update in writing to MSD’s Project Manager, which update shall contain information about the overall progress of the Study, recruitment
status, interim analysis (if results available), final analysis and other information relevant to the conduct of the Study. 
 3.9.3 In
addition to a Project Manager, each Party shall designate an alliance manager (the “Alliance Manager”), who shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information
and shall serve as the primary point of contact for any issues arising under this Agreement outside of the JDC. The Alliance Managers shall have the right to attend all JDC meetings and may bring to the attention of the JDC any matters or issues
either of them reasonably believes should be discussed and shall have such other responsibilities as the Parties may mutually agree in writing. 

3.9.4 In the event that an issue arises and the Alliance Managers cannot or do not, after good faith efforts, reach agreement on such issue,
such issue shall be submitted for resolution by the JDC. If there is a decision to be made by the JDC on which the members of the JDC cannot unanimously agree, the issue shall be elevated to the [***] for MSD and the Chief Executive Officer for
Company. In the event such escalation does not result in resolution or consensus: [***]. 
 3.10 Interim Analysis . Following interim
data readout at a predefined point set out in the Protocol, Company shall provide MSD with an electronic copy of the interim Study data when available, the criteria of which shall be determined by the JDC within [***] of the formation of the JDC
(the “Interim Analysis”). 
 3.11 Final Analysis . Following Study Completion, Company shall provide MSD with an
electronic copy of then-available final Study data, including, as applicable and set forth for final readout in the clinical study plan for the Study, data relating to safety, progression free survival, overall responses rate, durable response rate,
and/or complete response rate (the “Final Analysis”). “Study Completion” [***]. 
 3.12
Regulatory Agreement. The Parties shall enter into the Regulatory Agreement no later than [***] after the Effective Date. It is understood and acknowledged by the Parties that positive
Clinical Data may be used to obtain label changes for the Compounds. In such event, the Parties will collaborate on regulatory matters in accordance with the Regulatory Agreement. 

3.13 Relationship . Except as expressly set forth in this Agreement, nothing in this Agreement shall: [***]
or (b) create an exclusive relationship between the Parties with respect to any Compound. Each Party acknowledges and agrees that nothing in this Agreement shall be construed as a representation or inference that the other Party will not
develop for itself, or enter into business relationships with other Third Parties regarding, any products, programs, studies (including combination studies), technologies or processes that are similar to or that may compete with the Combination or
any other product, program, technology or process, including [***] are not used or disclosed in connection therewith in violation of this Agreement. Notwithstanding the foregoing, or anything in this Agreement to the contrary, Company shall have no
right to include any PD-1 Antagonist other than the MSD Compound in the Study. 

  
 13 

 Confidential 
  

 3.14 Licensing . Nothing in this Agreement shall prohibit or restrict a Party from
licensing, assigning or otherwise transferring to an Affiliate or Third Party such Party’s Compound(s) [***] owned solely by such Party. A Party may license, assign or transfer to an Affiliate or Third Party such Party’s interest in the
[***] owned jointly by the Parties and/or [***], and in connection therewith [***] owned by the other Party, solely to the extent such licensee, assignee or transferee agrees in writing to be bound by the terms of this Agreement with respect to such
[***]. For purposes of clarity, any assignment or transfer of this Agreement must comply with Article 18 of this Agreement. 
  

	4.	 Protocol, Statistical Analysis Plan and Informed Consent; Certain Covenants . 

4.1 Protocol and Statistical Analysis Plan . A Protocol and the draft statistical analysis plan for the
Study have been agreed to by the Parties as of the Effective Date and are attached hereto as Appendix A. Through the JDC, Company shall (a) provide any subsequent revisions of the Protocol to MSD for MSD’s review
and comment, (b) consider in good faith any changes to the Protocol requested by MSD, and (c) incorporate any changes requested by MSD with respect to MSD Compound. To the extent the JDC cannot agree unanimously regarding the contents of
the revised Protocol for final approval the matter shall be resolved in accordance with Section 3.9.4. Once the final Protocol has been approved in accordance with this Section 4.1, any material
changes to such approved final Protocol [***] shall require [***]. 
 4.1.1 Notwithstanding anything to the contrary contained herein,
[***], in its sole discretion, shall have the sole right to determine [***] and shall have the final decision on all matters relating to the [***] and any information regarding [***] included in the Protocol. 

4.1.2 Notwithstanding anything to the contrary contained herein, [***] in its sole discretion, shall have the sole right to determine [***]
and shall have the final decision on all matters relating to the [***] and any information regarding [***] included in the Protocol. 
 4.2
Informed Consent . Company shall prepare the patient informed consent form for the Study (which shall include provisions regarding the use of Samples in Sample Testing and the processing of Personal Data, including
Special Categories of Data, in accordance with this Agreement, including without limitation any data protection agreement entered into by the Parties) in consultation with MSD (it being understood and agreed that the portion of the informed consent
form relating to the Sample Testing of the MSD Compound shall be prepared by MSD and provided to Company by MSD). Any proposed changes to such form that relate to the MSD Compound, including Sample Testing of the MSD Compound, shall be subject to
MSD’s prior written consent. Any such proposed changes will be sent in writing to MSD’s Project Manager and MSD’s Alliance Manager. MSD will provide such consent, or a written explanation for why such consent is being withheld, within
[***] after MSD receives a copy of Company’s requested changes. 
 4.3 Financial Disclosure .
Company shall [***]. 

  
 14 

 Confidential 
  

 4.4 Transparency Reporting . 

4.4.1 With respect to any annual reporting period in which Company is not an entity that is required to make a Transparency Report under
Applicable Law, when requested, Company will use commercially reasonable efforts to provide to MSD data regarding payments or other transfers of value that MSD reasonably determines constitute “indirect” payments or other transfers of
value by MSD in the format requested by MSD and provided on a basis to be agreed upon by both Parties. 
 4.4.2 With respect to any annual
reporting period in which [***], Company will provide to MSD, in writing, Company’s point of contact for purposes of receiving information from MSD pursuant to this Section 4.4, along with such contact’s full
name, email address, and telephone number. Company may update such contact from time to time by notifying MSD in writing pursuant to Article 23 (Notices). Where applicable, MSD will provide to Company all such contact
information regarding the value of the MSD Compound provided for use in the Study required for such reporting. In the event that the value of the MSD Compound provided pursuant to this Section 4.4.2 changes, MSD shall
notify Company of such revised value and the effective date thereof. 
 4.4.3 For purposes of this Section 4.4,
“Transparency Report” means a transparency report in connection with reporting payments and other transfers of value made to health care professionals or facilities, including, without limitation, teaching hospitals, investigators,
steering committee members, data monitoring committee members, and consultants in connection with the Study in accordance with reporting requirements under Applicable Law, including, without limitation, the Physician Payment Sunshine Act and state
gift laws, and the European Federation of Pharmaceutical Industries and Associations Disclosure Code, or a Party’s applicable policies to the extent such policies have been previously provided to and acknowledged in writing by the other Party.

  

	5.	 Adverse Event Reporting . 

5.1 Pharmacovigilance Agreement . Company will be solely responsible for compliance with all Applicable Law
pertaining to safety reporting for the Study and related activities. The Parties (or their respective Affiliates) will execute a pharmacovigilance agreement inclusive of safety management plan details (the “Pharmacovigilance
Agreement”) prior to the initiation of clinical activities under the Study, but in any event within [***] after the Effective Date, to ensure the exchange of relevant safety data within appropriate timeframes and in an appropriate format to
enable the Parties to fulfill local and international regulatory reporting obligations and to facilitate appropriate safety reviews. In the event of any inconsistency between the terms of this Agreement and the Pharmacovigilance Agreement, [***] The
Pharmacovigilance Agreement will include safety data exchange procedures governing the coordination of collection, investigation, reporting, and exchange of information concerning any adverse experiences, pregnancy reports, and any other safety
information arising from or related to the use of the [***] in the Study, consistent with Applicable Law. Such guidelines and procedures shall be in accordance with, and enable the Parties and their Affiliates to fulfill, local and international
regulatory reporting obligations to Regulatory Authorities. For the avoidance of doubt, the obligations to provide safety data under the Pharmacovigilance Agreement will be independent of any obligations to provide safety data pursuant to this
Agreement. 

  
 15 

 Confidential 
  

 5.2 Transmission of SAEs . Company will transmit to MSD
all serious adverse events (“SAEs”) as follows: 
 5.2.1 For drug-related fatal and life-threatening SAEs, and newly
diagnosed cancer, Company will send a processed case (on a CIOMS-1 form in English) within [***] after receipt by Company of such SAEs. 

5.2.2 For all other SAEs, including non-drug-related fatal and life-threatening SAEs, Company will
send a processed case (on a CIOMS-1 form in English) within [***] after receipt by Company of such SAEs. 

5.2.3 Cases of disease progression will be handled as outlined in the Protocol, and if the Protocol specifies that such cases are collected as
SAEs, Company will transmit such cases to MSD within the applicable timeframe set forth in Section 5.2.1 or Section 5.2.2. 

5.2.4 For all other reportable information that includes: (1) overdose, exposure during pregnancy of lactation; and (ii) cases of
potential drug-induced liver injury where the patient was exposed to the MSD Compound (if required to be collected or identified per the Protocol), Company will transmit a processed case within [***] after receipt by Company of such information.

  

	6.	 Term and Termination . 

6.1 Term . The term of this Agreement shall commence on the Effective Date and shall continue in full force and effect until delivery
of the Final Analysis, unless terminated earlier by either Party pursuant to this Article 6 (the “Term”). 

6.2 Termination for Material Breach . Either Party may terminate this Agreement if the other Party commits
a material breach of this Agreement, and such material breach continues for [***] after receipt of written notice thereof from the non-breaching Party; provided that if such material breach cannot reasonably
be cured within [***], the breaching Party shall be given a reasonable period of time to cure such breach; provided further, that if such material breach is incapable of cure, then the notifying Party may terminate this Agreement effective after the
expiration of such [***] period. 
 6.3 Termination for Patient Safety . If either Party determines in
good faith, [***], that (a) the MSD Compound is being used in the Study in an unsafe manner or (b) performing or continuing to perform the Study may pose an unreasonable risk to patient safety, such Party shall promptly notify the other
Party of such determination. The Party receiving such notice may propose modifications to the Protocol or Study to address the safety issue identified by the other Party and, if the notifying Party agrees, shall act to implement immediately such
modifications; provided, however, that if the notifying Party, in its sole discretion, believes that there is imminent danger to patients, such Party need not wait for the other Party to propose modifications and may instead terminate this Agreement
immediately upon written notice to such other Party. Furthermore, if the notifying Party, in its sole discretion, believes that any modifications proposed by the other Party will not resolve the patient safety issue, such Party may terminate this
Agreement effective upon written notice to such other Party. 

  
 16 

 Confidential 
  

 6.4 Termination for Regulatory Action; Other Reasons .
Either Party may terminate this Agreement immediately upon written notice to the other Party in the event that any Regulatory Authority takes any action, or raises any objection, that prevents the terminating Party from supplying its Compound(s) for
purposes of the Study. Additionally, either Party shall have the right to terminate this Agreement immediately upon written notice to the other Party in the event that it determines in its sole discretion to withdraw any applicable Regulatory
Approval for its Compound(s) or to discontinue development of its Compound(s) for medical, scientific or legal reasons. 
 6.5
Termination Related to Anti-Corruption Obligations . Either Party shall have the right to terminate this Agreement immediately upon written notice to the other Party, if such other Party fails to perform any of its obligations under
Section 13.4 or breaches any representation or warranty contained in Section 13.4. Except as set forth in [***], the non-terminating Party shall have no
claim against the terminating Party for compensation for any loss of whatever nature by virtue of the termination of this Agreement in accordance with this Section 6.5. 

6.6 Return of MSD Compound . In the event that this Agreement is terminated, or in the event Company
remains in possession (including through any Affiliate or Subcontractor) of MSD Compound at the time this Agreement expires, Company shall, at MSD’s sole discretion, promptly either return or destroy all unused MSD Compound pursuant to
MSD’s instructions. If MSD requests that Company destroy the unused MSD Compound, Company shall provide written certification of such destruction. Notwithstanding the foregoing, in the event this Agreement is terminated by MSD pursuant to any
of Sections 6.2 or 6.5 and MSD requests that all unused MSD Compound be returned, Company shall promptly return the unused MSD Compound to MSD at Company’s expense. 

6.7 Survival . The provisions of [***] shall survive the expiration or termination of this
Agreement. 
 6.8 No Prejudice . Termination of this Agreement shall be without prejudice to any claim or
right of action of either Party against the other Party for any prior breach of this Agreement. 
 6.9 Confidential
Information . Upon termination of this Agreement, each Party and its Affiliates shall promptly return to the Disclosing Party [***] furnished to the Receiving Party by the Disclosing Party; provided, however that the Receiving
Party may retain one (1) copy of such Confidential Information in its confidential files, solely for purposes of exercising the Receiving Party’s rights hereunder, satisfying its obligations hereunder or complying with any legal proceeding
or requirement with respect thereto, and provided further that the Receiving Party shall not be required to erase electronic files created in the ordinary course of business during automatic system back-up
procedures pursuant to its electronic record retention and destruction practices that apply to its own general electronic files and information so long as such electronic files are (a) maintained only on centralized storage servers (and not on
personal computers or devices), (b) not accessible by any of its personnel (other than its information technology specialists), and (c) are not otherwise accessed subsequently except with the written consent of the Disclosing Party or as
required by law or legal process. Such retained copies of Confidential Information shall remain subject to the confidentiality and non-use obligations herein. 

  
 17 

 Confidential 
  

 6.10 Manufacturing Costs . In the event of termination by MSD pursuant to any of
Sections 6.2 or 6.5 above, MSD shall be entitled to [***]. 
  

	7.	 Costs of Study . 

The Parties agree that: [***]. 
  

	8.	 Supply and Use of the Compounds . 

8.1 Supply of the Compounds . Subject to the terms and conditions of this Agreement, each of Company and
MSD and/or its Affiliate(s) will use commercially reasonable efforts to supply, or cause to be supplied, the quantities of its respective Compound(s) as are set forth in Appendix B, on the timelines set forth in
Appendix B, in each case, for use in the Study. If the Protocol is changed in accordance with Article 4 in such a manner that may affect the quantities of Compound(s) to be provided or the timing
for providing such quantities, the Parties shall amend Appendix B to reflect any changes required to be consistent with the Protocol. Each Party shall also provide to the other Party a contact person for the supply of its
Compound(s) under this Agreement. Notwithstanding the foregoing, or anything to the contrary herein, in the event that a Party is: (a) not supplying its Compound(s) in accordance with the terms of this Agreement, then the other Party shall have
no obligation to supply its Compound(s); or (b) allocating under Section 8.10, then the other Party may allocate proportionally. 

8.2 Clinical Quality Agreement . Within [***] after the Effective Date of this Agreement, but in any event
before any supply of MSD Compound hereunder, the Parties (or their respective Affiliates) shall enter into a quality agreement that shall address and govern issues related to the quality and handling of clinical drug supply to be supplied by the
Parties for use in the Study (the “Clinical Quality Agreement”). In the event of any inconsistency between the terms of this Agreement and the Clinical Quality Agreement, [***]. The Clinical Quality Agreement shall, among other
things: (a) detail classification of any Compound found to have a Non-Conformance; (b) include criteria for Manufacturer’s Release and related certificates and documentation; (c) include
criteria and timeframes for acceptance of MSD Compound; (d) include procedures for the resolution of disputes regarding any Compounds found to have a Non-Conformance; and (e) include provisions
governing the recall of Compounds. 
 8.3 Minimum Shelf Life Requirements . Each Party shall use
commercially reasonable efforts to supply its Compound(s) hereunder with an adequate remaining shelf life at the time of Delivery to meet the Study requirements. 

8.4 Provision of Compounds . 

8.4.1 MSD and/or its Affiliate(s) will deliver the MSD Compound [***] to Company’s, or its designee’s, location as specified by
Company (“Delivery” with respect to such MSD Compound). Title and risk of loss for the MSD Compound [***]. All costs associated with the subsequent transportation, warehousing and distribution of MSD Compound shall be borne by

  
 18 

 Confidential 
  

 
Company. Company will, or will cause its designee to: (a) take delivery of the MSD Compound supplied hereunder; (b) perform the acceptance (including testing) procedures allocated to it
under the Clinical Quality Agreement; (c) subsequently label and pack the MSD Compound (in accordance with Section 8.5); and promptly ship the MSD Compound to the Study sites for use in the Study, in compliance with
cGMP, GCP and other Applicable Law and the Clinical Quality Agreement; and (d) provide, from time to time at the reasonable request of MSD, the following information: any applicable chain of custody forms,
in-transport temperature recorder(s), records and receipt verification documentation, such other transport or storage documentation as may be reasonably requested by MSD, and usage and inventory reconciliation
documentation related to the MSD Compound. 
 8.4.2 Company is solely responsible, at its own cost, for supplying (including all
Manufacturing, acceptance and release testing) the Company Compounds for the Study, and the subsequent handling, storage, transportation, warehousing and distribution of the Company Compounds supplied hereunder. Company shall ensure that all such
activities are conducted in compliance with cGMP, GCP and other Applicable Law and the Clinical Quality Agreement. For purposes of this Agreement, the “Delivery” of a given quantity of each Company Compound shall be deemed to occur
when [***]. 
 8.5 Labeling and Packaging; Use, Handling and Storage . 

8.5.1 The Parties’ obligations with respect to the labeling and packaging of the Compounds are as set forth in the Clinical Quality
Agreement. Notwithstanding the foregoing or anything to the contrary contained herein, MSD and/or its Affiliate(s) shall provide the MSD Compound to Company in the form of [***], and Company shall be responsible for labeling, packaging and
leafleting such MSD Compound in accordance with the terms and conditions of the Clinical Quality Agreement and otherwise in accordance with all Applicable Law, including cGMP, GCP, and health, safety and environmental protections. 

8.5.2 Company shall: (a) use the MSD Compound solely for purposes of performing the Study; (b) not use the MSD Compound in any
manner that is inconsistent with this Agreement or for any commercial purpose; and (c) label, use, store, transport, handle and dispose of the MSD Compound in compliance with Applicable Law and the Clinical Quality Agreement, as well as
all instructions of MSD. Company shall not reverse engineer, reverse compile, disassemble or otherwise attempt to derive the composition or underlying information, structure or ideas of the MSD Compound, and in particular shall not analyze the MSD
Compound by physical, chemical or biochemical means except as necessary to perform its obligations under the Clinical Quality Agreement. 

8.6 Product Specifications . A certificate of analysis shall accompany each shipment of the MSD Compound to
Company. Upon request, Company shall provide MSD with a certificate of analysis covering [***] shipment of the Company Compounds used in the Study. 

8.7 Changes to Manufacturing . Each Party may make changes from time to time to its Compound(s) or the
Manufacturing Site, provided that such changes shall be in accordance with the Clinical Quality Agreement. 

  
 19 

 Confidential 
  

 8.8 Product Testing; Noncompliance . 

8.8.1 After Manufacturer’s Release. After Manufacturer’s Release of the MSD Compound and concurrently with Delivery of the
MSD Compound to Company, MSD and/or its Affiliate(s) shall provide Company with such certificates and documentation as are described in the Clinical Quality Agreement (“Disposition Package”). Company shall, within the time defined
in the Clinical Quality Agreement, perform, with respect to the MSD Compound, the acceptance (including testing) procedures allocated to it under the Clinical Quality Agreement. Company shall be solely responsible for taking all steps necessary to
determine that MSD Compound or Company Compounds, as applicable, is suitable for release before making such MSD Compound or Company Compounds, as applicable, available for human use, and MSD and/or its Affiliate(s) shall provide cooperation or
assistance as reasonably requested by Company in connection with such determination with respect to the MSD Compound. For clarity, Company’s obligations under the immediately preceding sentence with respect to the MSD Compound shall consist of
the performance of acceptance testing procedures and review of the certificates of analysis and other documentation that Company is required to review pursuant to the Clinical Quality Agreement. Company shall be responsible for storage and
maintenance of the MSD Compound until it is tested and/or released, which storage and maintenance shall be in compliance with (a) the Specifications for the MSD Compound, the Clinical Quality Agreement and Applicable Law and (b) any
specific storage and maintenance requirements as may be provided by MSD from time to time. Company shall be responsible for any failure of the MSD Compound to meet the Specifications to the extent caused by shipping, storage or handling conditions
after Delivery to Company hereunder. 
 8.8.2 Non-Conformance. 

(a) In the event that either Party becomes aware that any Compound may have a
Non-Conformance, despite testing and quality assurance activities (including any activities conducted by the Parties under Section 8.8.1), such Party shall immediately notify the
other Party in accordance with the procedures of the Clinical Quality Agreement. The Parties shall investigate any Non-Conformance in accordance with Section 8.9 (Investigations) and
any discrepancy between them shall be resolved in accordance with Section 8.8.3. 
 (b) In the
event that any proposed or actual shipment of the MSD Compound (or portion thereof) shall be agreed to have a Non-Conformance at the time of Delivery to Company, then unless otherwise agreed to by the Parties,
MSD and/or its Affiliate(s) shall replace such MSD Compound as is found to have a Non-Conformance (with respect to MSD Compound that has not yet been administered in the course of performing the Study). Unless
otherwise agreed to by the Parties in writing, [***] with respect to any MSD Compound that is found to have a Non-Conformance at the time of Delivery shall be [***]; provided that, for clarity, [***]. In the
event MSD Compound is lost or damaged [***]; provided that Company shall [***]; and provided further that [***]. 

  
 20 

 Confidential 
  

 (c) Company shall be responsible for, and MSD shall have no obligation or
liability with respect to, any Company Compound supplied hereunder that is found to have a Non-Conformance. Company shall replace any Company Compound as is found to have a
Non-Conformance (with respect to Company Compound that has not yet been administered in the course of performing the Study). Unless otherwise agreed to by the Parties in writing, [***] with respect to any
Company Compound that is found to have a Non-Conformance at the time of Delivery shall be [***]; provided that, for clarity, [***]. 

8.8.3 Resolution of Discrepancies. Disagreements regarding any determination of Non-Conformance
by Company shall be resolved in accordance with the provisions of the Clinical Quality Agreement. 
 8.9
Investigations. The process for investigations of any Non-Conformance shall be handled in accordance with the Clinical Quality Agreement. 

8.10 Shortage; Allocation . In the event that a Party’s Compound(s) is in short supply such that a
Party reasonably believes in good faith that it will not be able to fulfill its supply obligations hereunder with respect to its Compound(s), such Party will provide prompt written notice to the other Party thereof (including the shipments of
Compound hereunder expected to be impacted and the quantity of its Compound(s) that such Party reasonably determines it will be able to supply) and the Parties will promptly discuss such situation (including how the quantity of Compound(s) that such
Party is able to supply hereunder will be allocated within the Study). In such event, the Party experiencing such shortage shall (a) use its commercially reasonable efforts to remedy the situation giving rise to such shortage and to take action
to minimize the impact of the shortage on the Study, and (b) [***]. 
 8.11 Records; Audit Rights.
Company shall keep complete and accurate records pertaining to its use and disposition of MSD Compound (including its storage, shipping (cold chain) and chain of custody activities) and, upon request of MSD, shall make such records open to review by
MSD for the purpose of conducting investigations for the determination of MSD Compound safety and/or efficacy and Company’s compliance with this Agreement with respect to the MSD Compound. 

8.12 Quality. Quality matters related to the Manufacture of the Compounds shall be governed by the terms of
the Clinical Quality Agreement in addition to the relevant quality provisions of this Agreement. 
 8.13 Quality
Control. Each Party shall implement and perform operating procedures and controls for sampling, stability and other testing of its Compound(s), and for validation, documentation and release of its Compound(s) and such other quality
assurance and quality control procedures as are required by the Specifications, cGMPs and the Clinical Quality Agreement. 
 8.14
Audits and Inspections. The Parties’ audit and inspection rights related to this Agreement shall be governed by the terms of the Clinical Quality Agreement. 

8.15 Recalls. Recalls of the Compounds shall be governed by the terms of the Clinical Quality Agreement.

  
 21 

 Confidential 
  

 8.16 VAT. 

8.16.1 It is understood and agreed between the Parties that any payments made and any other consideration given under this Agreement are each
exclusive of any value added or similar tax (“VAT”), which shall be added thereon as applicable and at the relevant rate. Subject to Section 8.16.1, where VAT is properly charged by the supplying Party and
added to a payment made or other consideration provided (as applicable) under this Agreement, the Party making the payment or providing the other consideration (as applicable) will pay the amount of VAT properly chargeable only on receipt of a valid
tax invoice from the supplying Party issued in accordance with the laws and regulations of the country in which the VAT is chargeable. Each Party agrees that it shall provide to the other Party any information and copies of any documents within its
Control to the extent reasonably requested by the other Party for the purposes of (a) determining the amount of VAT chargeable on any supply made under this Agreement, (b) establishing the place of supply for VAT purposes, or
(c) complying with its VAT reporting or accounting obligations. 
 8.16.2 Where one Party or its Affiliate (the “First
Party”) is treated as making supply of goods or services in a particular jurisdiction (for VAT purposes) [***], and the other Party or its Affiliate (the “Second Party”) is treated as receiving such supply in the same
jurisdiction, thus resulting in an amount of VAT being properly chargeable on such supply, the Second Party shall only be obliged to pay to the First Party the amount of VAT properly chargeable on such supply (and no other amount). The Second Party
shall pay such VAT to the First Party on receipt of a valid VAT invoice from the First Party (issued in accordance with the laws and regulations of the jurisdiction in which the VAT is properly chargeable). Each Party agrees to (a) use its
reasonable efforts to determine and agree the value of the supply that has been made and, as a result, the corresponding amount of VAT that is properly chargeable and (b) provide to the other Party any information or copies of documents in its
Control as are reasonably necessary to evidence that such supply will take, or has taken, place in the same jurisdiction (for VAT purposes). 
  

	9.	 Confidentiality. 

9.1 Confidential Information. Subject to Section 13.4.8, Company and MSD agree to hold in confidence any
Confidential Information provided by or on behalf of the other Party, and neither Party shall use Confidential Information of the other Party except to fulfill such Party’s obligations under this Agreement or exercising its rights. Without
limiting the foregoing, the Receiving Party may not, without the prior written permission of the Disclosing Party, disclose any Confidential Information of the Disclosing Party to any Third Party except to the extent disclosure (a) is required
by Applicable Law or the rules of a security exchange; (b) is permitted pursuant to the terms of this Agreement; or (c) is necessary for the conduct of the Study, and in each case ((a) through (c)), provided that the Receiving Party shall
provide reasonable advance notice to the Disclosing Party before making such disclosure. For the avoidance of doubt, Company may, without MSD’s consent, disclose Confidential Information to clinical trial sites and clinical trial investigators
performing the Study, the data safety monitoring and advisory board relating to the Study, and Regulatory Authorities working with Company on the Study, in each case, to the extent necessary for the performance of the Study and provided that such
Persons (other than governmental entities) are bound by an obligation of confidentiality at least as stringent as the obligations contained herein. 

  
 22 

 Confidential 
  

 9.2 Inventions. Notwithstanding the foregoing: (a) Inventions that constitute
Confidential Information and are jointly owned by the Parties, shall constitute the Confidential Information of both Parties and each Party shall have the right to use and disclose such Confidential Information consistent with
Articles 10, 11 and 12; and (b) Inventions that constitute Confidential Information and are solely owned by one Party shall constitute the Confidential Information of that Party and each Party shall have
the right to use and disclose such Confidential Information consistent with Articles 10, 11 and 12. 

9.3 Personal Identifiable Data. All Confidential Information containing Personal Data (including Special
Categories of Data) shall be handled in accordance with all Data Protection Laws. 
  

	10.	 Intellectual Property. 

10.1 Joint Ownership and Prosecution. 

10.1.1 All rights to all Inventions relating to, or covering, [***] that are not MSD Inventions or Company Inventions [***] (each a
“Jointly Owned Invention”) shall be owned jointly by Company and MSD [***] 
 10.1.2 Each Party shall have the right to
[***]. 
 10.1.3 [***] 

10.1.4 Except as expressly provided in this Agreement and in furtherance and not in limitation of Section 9.1, each
Party agrees to file no patent application based on the other Party’s Confidential Information, and to not give any assistance to any Third Party for such application, without the other Party’s prior written authorization. 

10.1.5 [***] shall have the first right, but not the obligation, to initiate legal action to enforce all Joint Patents against infringement
and to protect all Jointly Owned Inventions from misappropriation by any Third Party, [***] or to defend any declaratory judgment action relating thereto, at its sole expense. In the event that [***] fails to initiate or defend any such action
within [***] after being first notified of such infringement, [***] shall have the right to do so at its sole expense. [***] shall have the first right, but not the obligation, to initiate legal action to enforce any applicable Joint Patent against
infringement and to protect all applicable Jointly Owned Inventions from misappropriation by any Third Party, [***] or to defend any declaratory judgment action relating thereto, at its sole expense. In the event that [***] fails to initiate or
defend any such action within [***] after being first notified of such infringement, [***] shall have the right to do so at its sole expense. [***]. 

10.1.6 If one Party brings any prosecution or enforcement action or proceeding against a Third Party with respect to any [***], the second
Party agrees to be joined as a party plaintiff where necessary and to give the first Party reasonable assistance and authority to file and prosecute the suit. The costs and expenses of the Party bringing suit under this
Section 10.1.6 shall be borne by such Party, and any damages or other monetary awards recovered shall be shared as follows: [***]. A settlement or consent judgment or other voluntary final disposition of a suit under this
Section 10.1.6 may not be entered into without the consent of the Party not bringing the suit. 

  
 23 

 Confidential 
  

 10.2 Inventions Owned by Company. Notwithstanding
anything to the contrary contained in Section 10.1, the Parties agree that all rights to Inventions relating solely to, or covering solely, a Company Compound or a Company Class Compound, and any improvements related
solely to, or solely covering, a Company Compound or a Company Class Compound, [***], are the exclusive property of Company (“Company Inventions”). Company shall be entitled to file and prosecute in its own name relevant patent
applications and to own resultant patent rights for any Company Invention. For the avoidance of doubt, any Invention [***] 
 10.3
Inventions Owned by MSD. Notwithstanding anything to the contrary contained in Section 10.1, the Parties agree that all rights to Inventions relating solely to, or covering solely,
the MSD Compound or a PD-1 Antagonist, and any improvements related solely to, or solely covering, the MSD Compound or a PD-1 Antagonist, [***], are the exclusive
property of MSD (“MSD Inventions”). MSD shall be entitled to file and prosecute in its own name relevant patent applications and to own resultant patent rights for any MSD Invention. For the avoidance of doubt, any Invention [***]

 10.4 Mutual Freedom to Operate for Combination Inventions. 

10.4.1 Company License to MSD. Company hereby grants to MSD a non-exclusive, worldwide,
royalty-free, fully paid-up, transferable and sublicensable license [***]. 
 10.4.2 MSD License
to Company. MSD hereby grants to Company a non-exclusive, worldwide, royalty-free, fully paid-up, transferable and sublicensable license [***]. 

10.4.3 No Other Rights. For clarity, the terms of this Section 10.4 do not provide MSD or Company with any
rights, title or interest or any license to the other Party’s intellectual property rights [***]. 
 10.4.4 Termination.
[***].  
 10.5 Right of First Negotiation. 

10.5.1 Notice. From the Effective Date until [***] (the “ROFN Period”), if (a) Company seeks to license or enter
into any collaboration or similar transaction granting a Third Party rights to develop or commercialize a Company Compound (each such license, collaboration or any similar transaction granting a Third Party such rights, a “ROFN
Transaction”) or (b) Company receives a bona fide unsolicited offer from a Third Party for a ROFN Transaction that the Company does not reject without further discussions with such Third Party (each such offer, an
“Unsolicited Offer”), Company shall promptly notify MSD in writing of the existence of such proposed ROFN Transaction or Unsolicited Offer, as applicable. 

10.5.2 MSD Right. Following notification to MSD by Company of the first proposed ROFN Transaction or Unsolicited Offer received by
Company during the ROFN Period, MSD shall have the right, but not the obligation, to negotiate and enter into a transaction with Company to develop and commercialize such Company Compound(s) (the “MSD Right”). If MSD

  
 24 

 Confidential 
  

 
desires to exercise the MSD Right, it shall so notify Company in writing within [***] after receiving such written notice from Company. Thereafter, the Parties shall negotiate the terms of a
proposed transaction for a period expiring upon the date that is [***] after MSD delivers such written notice to Company (the “Negotiation Period”). The Negotiation Period may be extended for additional periods of time as agreed by
the Parties in writing before expiration of the Negotiation Period. For avoidance of doubt, expiration of the ROFN Period or MSD’s decision to not exercise the MSD Right shall not affect the Term nor change either Party’s obligations to
perform under this Agreement; [***]. 
 10.5.3 Limitations. If, once Company has notified MSD of a ROFN Transaction or Unsolicited
Offer, (a) MSD does not timely exercise the MSD Right within the foregoing [***] period, or (b) the Parties do not enter into definitive contractual documentation for the applicable transaction during the Negotiation Period, Company shall
be free to negotiate and enter into such ROFN Transaction with any Third Party, with no further obligation to MSD with respect thereto. Company’s obligation to notify MSD under Section 10.5.1 and the MSD Right under
Section 10.5.2 shall immediately expire upon any Change of Control of Company, and [***].  
  

	11.	 Reprints; References in Publication. 

Consistent with applicable copyright and other laws, each Party may use, refer to, and disseminate reprints of scientific, medical and other
published articles and materials from journals, conferences and/or symposia relating to the Study that disclose the name of a Party, provided, however, that such use does not constitute an endorsement of any commercial product or service by the
other Party. 
  

	12.	 Publications; Press Releases. 

12.1 Clinical Trial Registry. Company shall register the Study with the Clinical Trials Registry located at
www.clinicaltrials.gov and is committed to timely publication of the results following Study Completion, after taking appropriate action to secure intellectual property rights (if any) arising from the Study. The publication of the results of the
Study will be in accordance with the Protocol. 
 12.2 Publication. Each Party shall use reasonable
efforts to publish or present the results of the Study in scientific papers or in scientific conferences in accordance with accepted scientific practice and in accordance with this Section 12.2. The Parties agree that prior
to submission of the results of the Study for publication or presentation or any other dissemination of such results including oral dissemination, the publishing Party shall invite the other to comment on the content of the material to be published,
presented, or otherwise disseminated according to the following procedure: 
 12.2.1 At least [***], the publishing Party shall provide to
the other Party the full details of the proposed publication, presentation, or dissemination in an electronic version (cd-rom or email attachment), and the
non-publishing Party shall have the right to review and comment on such proposed publication. Upon written request from the other Party, the publishing Party agrees not to submit data for
publication/presentation/dissemination for an additional [***] in order to allow for actions to be taken to preserve rights for patent protection. 

  
 25 

 Confidential 
  

 12.2.2 The publishing Party shall give reasonable consideration to any request by the other
Party made within the periods mentioned in Section 12.2.1 to modify the proposed publication and the Parties shall work in good faith and in a timely manner to resolve any issue regarding the content for publication. 

12.2.3 The publishing Party shall, upon reasonable request by the other Party, remove the Confidential Information of the other Party from the
proposed publication before finalizing the publication. 
 12.3 Press Releases. Promptly following the
Effective Date, Company may issue the press release attached hereto as Appendix D. Unless otherwise required by Applicable Law or rules of a securities exchange upon which a Party’s securities are listed, neither Party shall make any
other public announcement concerning this Agreement without the prior written consent of the other Party. To the extent a Party desires to make such public announcement, such Party shall provide the other Party with a draft thereof at least [***]
prior to the date on which such Party would like to make the public announcement. If a Party believes a disclosure concerning this Agreement is necessary to comply with Applicable Law or rules of a securities exchange, such Party shall promptly
inform the other Party of the disclosure that is being sought, and consult and cooperate fully with the other Party in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Any information disclosed shall
remain otherwise subject to the confidentiality and non-use provisions of this Section, and the Party disclosing such information shall take all steps reasonably necessary, including without limitation
obtaining an order of confidentiality, to ensure the continued confidential treatment of such information. 
  

	13.	 Representations and Warranties; Disclaimers. 

13.1 Due Authorization. Each of Company and MSD represents and warrants to the other that: (a) it has
the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (b) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this
Agreement and the performance of its obligations hereunder; and (c) this Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation of such Party that is enforceable against it
in accordance with its terms. 
 13.2 Compounds. 

13.2.1 Company Compounds. Company hereby represents and warrants to MSD that: (a) Company has the full right, power and authority
to grant all of the licenses granted to MSD under this Agreement; and (b) Company Controls the Company Compounds. 
 13.2.2 MSD
Compound. MSD hereby represents and warrants to Company that: (a) MSD has the full right, power and authority to grant all of the licenses granted to Company under this Agreement; and (b) MSD and/or its Affiliate(s) Controls the MSD
Compound. 
 13.3 Results. Company does not undertake that the Study shall lead to any particular result,
nor is the success of the Study guaranteed. Neither Party shall be liable for any use that the other Party may make of the Clinical Data nor for advice or information given in connection therewith. 

  
 26 

 Confidential 
  

 13.4 Anti-Corruption. 

13.4.1 In performing their respective obligations hereunder, the Parties acknowledge that the corporate policies of Company and MSD and their
respective Affiliates require that each Party’s business be conducted within the letter and spirit of the law. By signing this Agreement, each Party agrees to conduct the business contemplated herein in a manner that is consistent with all
Applicable Law, including the Stark Act, Anti-Kickback Statute, Sunshine Act, and the U.S. Foreign Corrupt Practices Act, good business ethics, and its ethics and other corporate policies and agrees to abide by the spirit of the other Party’s
guidelines, which may be provided by such other Party from time to time. 
 13.4.2 Specifically, each Party represents and warrants that it
has not, and covenants that it, its Affiliates, and its and its Affiliates’ directors, employees, officers, and anyone acting on its behalf, will not, in connection with the performance of this Agreement, directly or indirectly, make, promise,
authorize, ratify or offer to make, or take any action in furtherance of, any payment or transfer of anything of value for the purpose of influencing, inducing or rewarding any act, omission or decision to secure an improper advantage; or improperly
assisting it in obtaining or retaining business for it or the other Party, or in any way with the purpose or effect of public or commercial bribery. 

13.4.3 Neither Party shall contact, or otherwise knowingly meet with, any Government Official for the purpose of discussing activities arising
out of or in connection with this Agreement, without the prior written approval of the other Party, except where such meeting is consistent with the purpose and terms of this Agreement and in compliance with Applicable Law. 

13.4.4 Each Party represents and warrants that it (a) is not excluded, debarred, suspended, proposed for suspension or debarment, in
Violation or otherwise ineligible for government programs; and (b) has not employed or subcontracted with any Person for the performance of the Study who is excluded, debarred, suspended, proposed for suspension or debarment, or is in Violation
or otherwise ineligible for government programs. 
 13.4.5 Each Party represents and warrants that, except as disclosed to the other in
writing prior to the Effective Date, such Party: (a) does not have any interest that directly or indirectly conflicts with its proper and ethical performance of this Agreement; (b) shall maintain arm’s length relations with all Third
Parties with which it deals for or on behalf of the other in performance of this Agreement; and (c) has provided complete and accurate information and documentation to the other Party, the other Party’s Affiliates and its and their
personnel in the course of any due diligence conducted by the other Party for this Agreement, including disclosure of any officers, employees, owners or Persons directly or indirectly retained by such Party in relation to the performance of this
Agreement who are Government Officials or relatives of Government Officials. Each Party shall make all further disclosures to the other Party as are necessary to ensure the information provided remains complete and accurate throughout the Term.
Subject to the foregoing, each Party agrees that it shall not hire or retain any Government Official to assist in its performance of this Agreement, with the sole exception of conduct of or participation in clinical trials under this Agreement,
provided that such hiring or retention shall be subject to the completion by the hiring or retaining Party of a satisfactory anti-corruption and bribery (e.g., FCPA) due diligence review of such Government Official. Each Party further covenants that
any future information and documentation submitted to the other Party as part of further due diligence or a certification shall be complete and accurate. 

  
 27 

 Confidential 
  

 13.4.6 Each Party shall have the right during the Term, [***], to conduct an investigation
and audit of the other Party’s activities, books and records, to the extent they relate to that other Party’s performance under this Agreement, to verify compliance with the terms of this Section 13.4. Each Party
shall provide commercially reasonable cooperation and grant commercially reasonable access to relevant documents and materials as reasonably required by the Party requesting such investigation and audit. 

13.4.7 Each Party shall use commercially reasonable efforts to ensure that all transactions under the Agreement are properly and accurately
recorded in all material respects on its books and records and that each document upon which entries in such books and records are based is complete and accurate in all material respects. Each Party further represents, warrants and covenants that
all books, records, invoices and other documents relating to payments and expenses under this Agreement are and shall be complete and accurate and reflect in reasonable detail the character and amount of transactions and expenditures. Each Party
shall maintain a system of internal accounting controls reasonably designed to ensure that no off-the-books or similar funds or accounts will be maintained or used in
connection with this Agreement. 
 13.4.8 Each Party agrees that in the event that the other Party believes in good faith that there has
been a possible violation of any provision of Section 13.4, such other Party may make full disclosure of such belief and related information needed to support such belief at any time and for any reason to any competent
government bodies and agencies, and to anyone else such Party determines in good faith has a legitimate need to know. 
 13.4.9 Each Party
shall comply with its own ethical business practices policy and any corporate integrity agreement (if applicable) to which it is subject, and shall conduct its Study related activities in accordance with Applicable Law. Each Party shall ensure that
all of its employees involved in performing its obligations under this Agreement are made specifically aware of the compliance requirements under this Section 13.4. In addition, each Party shall ensure that all such
employees participate in and complete mandatory compliance training to be conducted by each Party, including specific training on anti-bribery and corruption, prior to his/her performance of any obligations or activities under this Agreement. Each
Party shall certify its continuing compliance with the requirements under this Section 13.4 on a periodic basis during the Term in such form as may be reasonably specified by the other Party. 

13.4.10 Each Party shall have the right to terminate this Agreement immediately upon violation of this Section 13.4
in accordance with Section 6.5. 
 13.5 DISCLAIMER. EXCEPT AS EXPRESSLY
PROVIDED HEREIN, MSD MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE MSD COMPOUND, AND COMPANY MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE COMPANY COMPOUNDS. 

  
 28 

 Confidential 
  

	14.	 Insurance; Indemnification; Limitation of Liability. 

14.1 Insurance. Each Party warrants that it maintains a policy or program of insurance or self-insurance at
levels sufficient to support the indemnification obligations assumed herein. Upon request, a Party shall provide evidence of such insurance. 

14.2 Indemnification. 

14.2.1 Indemnification by Company. Company agrees to defend, indemnify and hold harmless MSD, its Affiliates, and its and their employees,
directors, subcontractors and agents from and against any loss, damage, reasonable costs and expenses (including reasonable attorneys’ fees and expenses) incurred in connection with any claim, proceeding, or investigation by a Third Party
arising out of [***] (a “Liability”), except to the extent that such Liability [***]. 
 14.2.2 Indemnification by
MSD. MSD agrees to defend, indemnify and hold harmless Company, its Affiliates, and its and their employees, directors, Subcontractors and agents from and against any Liability to the extent such Liability was directly caused by [***]. 

14.2.3 Procedure. The obligations of MSD and Company under this Section 14.2 are conditioned upon the
delivery of written notice to MSD or Company, as the case might be, of any potential Liability within a reasonable time after a Party becomes aware of such potential Liability. The indemnifying Party will have the right to assume the defense of any
suit or claim related to the Liability (using counsel reasonably satisfactory to the indemnified Party) if it has assumed responsibility for the suit or claim in writing; provided that the indemnified Party may assume the responsibility for such
defense to the extent the indemnifying Party does not do so in a timely manner. The indemnified Party may participate in (but not control) the defense thereof at its sole cost and expense. The Party controlling such defense (the “Defending
Party”) shall keep the other Party (the “Other Party”) advised of the status of such action, suit, proceeding or claim and the defense thereof and shall consider recommendations made by the Other Party with respect thereto.
The Defending Party shall not agree to any settlement of such action, suit, proceeding or claim without the prior written consent of the Other Party, which shall not be unreasonably withheld. The Defending Party, but solely to the extent the
Defending Party is also the indemnifying Party, shall not agree to any settlement of such action, suit, proceeding or claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Other Party
from all liability with respect thereto or that imposes any liability or obligation on the Other Party without the prior written consent of the Other Party. 

14.2.4 Study Subjects. Company shall not offer compensation on behalf of MSD to any Study subject or bind MSD to any indemnification
obligations in favor of any Study subject. MSD shall not offer compensation on behalf of Company to any Study subject or bind Company to any indemnification obligations in favor of any Study subject. 

14.3 LIMITATION OF LIABILITY. IN NO EVENT SHALL EITHER PARTY (OR ANY OF ITS AFFILIATES OR SUBCONTRACTORS)
BE LIABLE TO THE OTHER PARTY UNDER ANY THEORY FOR, NOR SHALL ANY INDEMNIFIED PARTY HAVE THE RIGHT TO RECOVER, ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR OTHER SIMILAR DAMAGES OR ANY PUNITIVE DAMAGES OR ANY LOST PROFIT, 

  
 29 

 Confidential 
  

 
LOST SALE OR LOST OPPORTUNITY DAMAGES (WHETHER SUCH CLAIMED DAMAGES ARE DIRECT OR INDIRECT), WHETHER ARISING DIRECTLY OR INDIRECTLY OUT OF (A) THE MANUFACTURE OR USE OF ANY COMPOUND SUPPLIED
HEREUNDER OR (B) ANY BREACH OF OR FAILURE TO PERFORM ANY OF THE PROVISIONS OF THIS AGREEMENT OR ANY REPRESENTATION, WARRANTY OR COVENANT CONTAINED IN OR MADE PURSUANT TO THIS AGREEMENT, EXCEPT THAT SUCH LIMITATION SHALL NOT APPLY TO DAMAGES
PAID OR PAYABLE TO A THIRD PARTY BY AN INDEMNIFIED PARTY FOR WHICH THE INDEMNIFIED PARTY IS ENTITLED TO INDEMNIFICATION HEREUNDER OR WITH RESPECT TO DAMAGES ARISING OUT OF OR RELATED TO A PARTY’S BREACH OF ITS OBLIGATIONS UNDER THIS AGREEMENT
WITH RESPECT TO [***]. 
  

	15.	 Use of Name. 

Except as otherwise provided herein or required under Applicable Law, neither Party shall have any right, express or implied, to use in any
manner the name or other designation of the other Party or any other trade name, trademark or logo of the other Party for any purpose in connection with the performance of this Agreement without the other Party’s prior written consent. 

 

	16.	 Force Majeure. 

If, in the performance of this Agreement, one of the Parties is prevented, hindered or delayed by reason of any cause beyond such Party’s
reasonable control (e.g., war, riots, fire, strike, epidemics, pandemics, acts of terror, governmental laws), such Party shall be excused from performance to the extent that it is necessarily prevented, hindered or delayed (“Force
Majeure”). The non-performing Party shall notify the other Party of such Force Majeure within [***] after such occurrence by giving written notice to the other Party stating the nature of the event,
its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension of performance will be of no greater scope and no longer duration than is necessary and the non-performing
Party shall use commercially reasonable efforts to remedy its inability to perform. 
  

	17.	 Entire Agreement; Amendment; Waiver. 

This Agreement, together with the Appendices and Schedules hereto and the Related Agreements, constitutes the sole, full and complete
agreement by and between the Parties with respect to the subject matter of this Agreement, and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto, including but not limited to the [***]
(the “Prior CDA”), are superseded by this Agreement. As of the Effective Date, all confidential information exchanged under the Prior CDA shall be considered Confidential Information exchanged under this Agreement. In the event of a
conflict between a Related Agreement and this Agreement, the terms of this Agreement shall control. No amendments, changes, additions, deletions or modifications to or of this Agreement shall be valid unless reduced to writing and signed by the
Parties hereto. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of
the Party waiving such term or condition. The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by
said other Party whether of a similar nature or otherwise. 

  
 30 

 Confidential 
  

	18.	 Assignment and Affiliates. 

Neither Party shall assign or transfer this Agreement without the prior written consent of the other Party; provided, however, that either
Party may assign all or any part of this Agreement without the other Party’s consent: (a) to one or more of its Affiliates, and any and all rights and obligations of either Party may be exercised or performed by its Affiliates, provided in
each case, that such Affiliates agree to be bound by this Agreement and such Party shall remain responsible for compliance by its Affiliates with the terms and conditions of this Agreement and shall remain liable for any breaches by its Affiliates
of this Agreement; or (b) in connection with its Change of Control; further, provided, that in the case of Company, Company must notify MSD as soon as practically possible following execution of a definitive agreement with respect to a Change
of Control and, in any event, prior to the public announcement of the Change of Control and no later than [***] following execution of a definitive agreement with respect to a Change of Control). Any permitted assignee shall assume all obligations
of its assignor under this Agreement, and Company, including its acquiring party, shall further adopt reasonable procedures to prevent any use of: (i) Confidential Information of MSD and (ii) Clinical Data in any PD-1 Antagonist program, in each case, outside of Company’s rights to use such data and information under this Agreement. This Agreement shall be binding upon the successors and permitted assigns of the Parties
and the name of a Party appearing herein shall be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of the Agreement. Any assignment not in accordance with this
Article 18 shall be null, void and of no legal effect. 
  

	19.	 Change of Control. 

If Company undergoes a Change of Control in which the acquiring party owns or controls a competing
PD-1 Antagonist, then upon MSD’s request, the Parties and the acquiring party shall engage in good faith discussion and shall adopt reasonable procedures to be agreed by MSD to prevent the disclosure of
Sensitive Information beyond Company’s personnel having access to or knowledge of Sensitive Information prior to the Change of Control and other personnel of the Change of Control partner approved by MSD, and to control the dissemination of
Sensitive Information disclosed after the Change of Control to prevent the use of Sensitive Information for the development or commercialization of competing PD-1 Antagonist products. Such procedures shall
include provisions allowing designated management personnel to review and evaluate on a comparative basis business and technical plans and information regarding the Combination, the MSD Compound, and competing
PD-1 Antagonist products, in connection with portfolio decision-making (but not, for clarity, for use in development or commercialization of competing PD-1 Antagonist products). 
  

	20.	 Invalid Provision. 

If any provision of this Agreement is held to be illegal, invalid or unenforceable, the remaining provisions shall remain in full force and
effect and will not be affected by the illegal, invalid or unenforceable provision. In lieu of the illegal, invalid or unenforceable provision, the Parties shall negotiate in good faith to agree upon a reasonable provision that is legal, valid and
enforceable to carry out as nearly as practicable the original intention of the entire Agreement. 

  
 31 

 Confidential 
  

	21.	 No Additional Obligations. 

Company and MSD have no obligation to renew this Agreement or apply this Agreement to any clinical trial other than the Study. Nothing in this
Agreement obligates the Parties to enter into any other agreement (other than the Related Agreements) at this time or in the future. 
  

	22.	 Governing Law; Dispute Resolution. 

22.1 The Parties shall attempt in good faith to settle all disputes arising out of or in connection with this Agreement in an amicable manner.
Any claim, dispute or controversy arising out of or relating to this Agreement, including the breach, termination or validity hereof or thereof, shall be governed by and construed in accordance with the substantive laws of the State of New York,
without giving effect to its choice of law principles. 
 22.2 Nothing contained in this Agreement shall deny either Party the right to seek
injunctive or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed or maintained notwithstanding any ongoing discussions between the
Parties. 

  
 32 

 Confidential 
  

	23.	 Notices. 

All notices or other communications that are required or permitted hereunder shall be in writing and delivered personally, sent by facsimile
(and promptly confirmed by personal delivery or overnight courier), or sent by internationally-recognized overnight courier addressed as follows: 
 If to
Company, to: 
 IO Biotech ApS 

[***] 
 If to MSD, to: 

MSD International GmbH 
 MSD
International Business GmbH 
 [***] 

MSD International Business GmbH 

[***] 
 With copies (which shall not constitute
notice) to: 
 [***] 
  

	24.	 Relationship of the Parties. 

The relationship between the Parties is and shall be that of independent contractors, and does not and shall not constitute a partnership,
joint venture, agency or fiduciary relationship. Neither Party shall have the authority to make any statements, representations or commitments of any kind, or take any actions, that are binding on the other Party, except with the prior written
consent of the other Party to do so. All Persons employed by a Party will be the employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such
Party. 
  

	25.	 Counterparts and Due Execution. 

This Agreement and any amendment may be executed in any number of counterparts (including by way of facsimile or electronic transmission),
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument, notwithstanding any electronic transmission, storage and printing of copies of this Agreement from computers or printers. When
executed by the Parties, this Agreement shall constitute an original instrument, notwithstanding any electronic transmission, storage and printing of copies of this Agreement from computers or printers. For clarity, facsimile signatures and
signatures transmitted via PDF shall be treated as original signatures. 

  
 33 

 Confidential 
  

	26.	 Construction. 

Except where the context otherwise requires, wherever used, the singular will include the plural, the plural the singular, the use of any
gender will be applicable to all genders, and the word “or” is used in the inclusive sense (and/or). Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions
of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including” as used
herein shall be deemed to be followed by the phrase “without limitation” or like expression. The term “will” as used herein means shall. The terms “hereof”, “hereto”,
“herein” and “hereunder” and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement. References to “Article,”
“Section”, “Appendix” or “Schedule” are references to the numbered sections of this Agreement and the appendices attached to this Agreement, unless expressly stated otherwise. Except where the
context otherwise requires, references to this “Agreement” shall include the appendices attached to this Agreement. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of
strict construction will be applied against either Party hereto. 
 [Remainder of page intentionally left blank.] 

  
 34 

 Confidential 
  

 IN WITNESS WHEREOF, the respective representatives of the Parties have executed this
Agreement as of the Effective Date. 
  

			
	IO Biotech ApS
		
	By:	 	 
	
	 
	Name
	
	 
	Title
	
	 
	Date
	
	MSD International GmbH
		
	By:	 	 
	
	 
	Name
	
	 
	Title
	
	 
	Date
	
	MSD International Business GmbH
		
	By:	 	 
	
	 
	Name
	
	 
	TitleEX-10.14

 Exhibit 10.14 

Execution version 
 Service Agreement 

IO Biotech ApS – Mai-Britt Zocca 

 This service agreement is entered into between: 

IO Biotech ApS 
 [***] 

(the “Company”) 
 and 

Mai-Britt Zocca 
 (the
“CEO”) 
  

	1	 Date of employment 

 

	1.1	 With effect from 1 January 2018 the CEO is employed as Chief Executive Officer of the Company on the terms
and conditions set forth in this Service Agreement. The CEO has been CEO of the Company since 1 January 2015 and this Service Agreement replaces all previous service agreements between the parties. 

 

	1.2	 The CEO is registered as Chief Executive Officer of the Company with the Danish Business Authority.

  

	2	 The duties of the CEO 

 

	2.1	 The CEO is responsible for the daily management of the Company subject to the instructions and the guidelines
issued by the Board of Directors. 

  

	2.2	 The Board of Directors determines the directions applicable to the activities of the Company at any time. It is
the responsibility of the CEO towards the Board of Directors that the activities of the Company are carried out in accordance with these directions, the Company’s Articles of Association, and current legislation. 

 

	2.3	 Any and all matters outside the normal
day-to-day operation of the Company shall be submitted by the CEO to the Board of Directors. 

 

	2.4	 The CEO is entitled to sign on behalf of the Company in matters concerning the
day-to-day operations of the Company, subject to the restrictions in this Service Agreement and otherwise in accordance with the role of signature in the Company’s
Articles of Association. 

  

	3	 Working bours and other work 

 

	3.1	 The CEO has no fixed weekly working hours. 

 

	3.2	 The CEO is not entitled to overtime pay or standby allowance, and likewise the CEO is not entitled to take time
off in lieu of overtime. 

  

	3.3	 Upon execution of this Service Agreement, the CEO bolds the following other positions all of which have been
agreed and accepted by the Company effective from 1 January 2015: 

  

	 	-	 [***]; CEO and founder. 

	 	-	 [***], CEO and founder. 

 

	 	-	 [***], co-founder (minority shareholder), BD. 

 

	3.4	 The Company acknowledges and agrees that the CEO may continue the activities described in clause 3.3 as long as
these activities do not interfere with or hinder the fulfilment of her obligations under this Service Agreement. Except as listed in clause 3.3 above, the CEO shall not without the written consent from the Board of Directors be the owner of or an
active or dormant participant in any other commercial business or hold any paid or unpaid office, or take up any paid work, such consent shall not be unreasonably delayed or withheld. However, the Board of Directors of the Company may always oppose
the CEO’s involvement in competing activities or activities that in other respects are inconsistent with the CEO’s obligations under this Service Agreement. 

 

	3.5	 The CEO is entitled to make normal capital investments (in Danish: “kapitalanbringelse”) in
assets, which are usually the subject of such investment, and which do not include personal working efforts of any kind and/or decisive influence. 

  

	3.6	 The CEO shall inform the Chairman of the Board of Directors of any material personal financial problems that
may result in the CEO not being able to honour the CEO’s debts when due. 

  

	4	 Remuneration 

  

	4.1	 Effective from 1 January 2018, the annual gross salary on a full time basis amounts to DKK 1,800,000. The
salary is to be paid 1/12 monthly in arrears not later than on the last business day of each month to an account designated by the CEO. 

  

	4.2	 The gross salary is subject to a review either by the Chairman of the Board of Directors or the remuneration
committee once a year in January, and for the first time in January 2019. Any regulation of the gross salary will be effective from 1 January of the year in question. 

 

	5	 Pension 

  

	5.1	 The CEO is not covered by a pension scheme arranged by the Company. 

 

	6	 Bonus 

  

	6.1	 In addition to the remuneration in clause 4.1 the CEO shall be entitled to a milestone dependent bonus of up to
3 months’ salary. 

  

	6.2	 The milestones and the individual bonus amounts relating to such milestones shall be defined by the Board of
Directors on an annual basis or when existing milestones are met, whichever is sooner. The adjustment, if any, will be determined at the discretion of the Board of Directors. The Board of Directors decides at its own discretion to what extend
milestones in any given year have been met. 

  

	6.3	 The milestone bonus in force from time to time is to be further described in a separate document.

  

	6.4	 Bonus amounts do not generate other salary payments. 

  
 2 

	7	 Other benefits 

 

	7.1	 The Company will pay all the CEO’s expenses for a laptop computer, a mobile telephone and internet
connection at the CEO’s private address. 

  

	7.2	 Upon the actual termination of the employment – irrespective of cause – the CEO must upon request
from the Company return the above benefits not later than on the day when the CEO’s duty to work ceases. At this time the Company’s payment of private mobile telephone and internet connection will also cease. This applies, irrespective of
whether the CEO receives salary after this date. The CEO cannot exercise any lien on the above benefits. 

  

	7.3	 During any remaining part of the notice period the CEO will receive a monthly amount corresponding to the
actual tax value of the above benefits. 

  

	7.4	 Any tax consequences to the CEO arising out of the above benefits are of no concern to the Company.

  

	8	 Entertainment and travel expenses 

 

	8.1	 The CEO’s reasonable costs in connection with travel and entertainment in the interest of the Company will
be refunded by the Company subject to receipts in accordance with the Company’s guidelines in force from time to time. The CEO should account for travel and entertainment expenses soon as possible after the expenses have been paid.

  

	9	 Holidays 

  

	9.1	 The CEO is entitled to six weeks’ holiday with pay per calendar year. 

 

	9.2	 The holiday should be taken subject to agreement with the Chairman of the Board of Directors.

  

	9.3	 The CEO is obliged to take any remaining holidays during the notice period and will not be entitled to
compensation, if the CEO bas been unable to take the holidays prior to resignation. 

  

	9.4	 The CEO is not covered by the Danish Holiday Act. 

 

	10	 Sickness 

  

	10.1	 The CEO is entitled to receive full salary during periods of sickness. 

 

	10.2	 The Company may terminate this Service Agreement subject to three months’ written notice effective from
the end of a month, if, due to sickness, the CEO bas been unable to perform the obligations as CEO during a consecutive period of six months or in total eight months within a period of 12 months. 

 

	11	 Confidentiality, duty of loyalty, and return of materials 

 

	11.1	 The CEO has a duty of confidentiality with respect to everything that the CEO may learn in connection with the
performance of the CEO’s duties. The duty of confidentiality shall continue to apply after expiry of the employment. 

  
 3 

	11.2	 During the period or employment – including during a notice period – the CEO is obliged to observe a
duty of loyalty towards the Company. This includes inter alia but not exhaustively: 

  

	 	-	 that the CEO is not entitled to commence any activities or, directly or indirectly, be engaged in any
activities which directly or indirectly compete with the Company’s activities. 

  

	11.3	 Failure to observe the CEO’s duty of confidentiality and loyalty may have consequences for the CEO’s
employment. 

  

	11.4	 Upon the actual termination of the employment – irrespective of cause – the CEO must return all
materials and all assets in the CEO’s possession which belong to the Company or relate to the Company’s activities. No lien may be exercised on any materials belonging to the Company. 

 

	12	 Non-competition clause 

 

	12.1	 During the employment the CEO is not entitled to commence any activities or, directly or indirectly, be engaged
in any activities (as owner, director, employee, agent, consultant or the like) which, directly or indirectly, compete with the activities of the Company or any group-affiliated companies. 

 

	12.2	 Furthermore, the Company is entitled in its sole discretion to require that the CEO for a period of 12 months
after termination of the employment, calculated from the last day the CEO receives salary is not entitled to commence any activities or, directly or indirectly, be engaged in any activities (as owner, director, employee, agent, consultant or the
like) which, directly or indirectly, compete with the activities of the Company or any group-affiliated companies, subject to the Company in such case being obligated to pay compensation to the CEO during such period equal to the fixed remuneration
paid at the time of termination of the employment. The Company must invoke its right under this clause 12.2 no later than 30 days after the Company gives notice of termination (including in the case of summary dismissal) to the CEO or the CEO gives
notice of termination, as the case may be. 

  

	12.3	 Activities that competes directly or indirectly with the business of the Company and which the CEO hence is
prevented of being engaged in pursuant to clauses 12.1 and 12.2 shall encompass therapies targeting immune modulation for the treatment and prevention of cancer. 

 

	12.4	 The non-competition clause shall lapse if the employment is terminated
by the Company, without the CEO having given reasonable cause for such termination, or if the CEO terminates the employment, and the Company’s omission to fulfil its obligations has given the CEO valid reason for terminating the employment.

  

	12.5	 The non-competition clause will apply globally. 

  
 4 

	12.6	 Any breach of the non-competition clause may be subject to injunction.
Furthermore, the CEO will, apart from damages, be obliged to pay on agreed penalty (in Danish: konventionalbod) of DKK 100,000, each time a breach occurs. If the breach concerns an ongoing situation which is in breach of the non-competition clause, one breech is deemed to have occurred for each calendar month commenced, during which the breach continues. Payment by the CEO of damages and/or an agreed penalty will not cause the non-competition clause to terminate and will not exclude the Company from applying other statutory relief, including injunction. 

 

	12.7	 To the extent the Company obtains penalties and/or damages under this clause 12, the Company shall not be
entitled to obtain penalties and/or damages in respect of the same loss/breach under the shareholders’ agreement regarding the Company to which the CEO is a party with regard to the same subject matter. 

 

	13	 Non-solicitation clause 

 

	13.1	 During the employment and for a period of 12 months after the termination of the employment – irrespective
of cause – calculated from the last day the CEO received salary, the CEO is not entitled, directly or indirectly, to have any commercial contact, including by employment, with companies or persons who at any time whatsoever within the last 18
months prior to the date of termination have been customers of or had commercial relations to the Company or any group-affiliated companies. 

  

	13.2	 No separate compensation is paid for undertaking this non-solicitation
clause. 

  

	13.3	 Any breach of the non-solicitation clause may be subject to injunction.
Furthermore, the CEO will, apart from damages, be obliged to pay an agreed penalty (in Danish: konventionalbod) of DKK 100,000, for each time a breach occurs. If the breach concerns an ongoing situation which is in breach of the non-solicitation clause, one breach is deemed to have occurred for each calendar month commenced, during which the breach continues. Payment by the CEO of damages and/or agreed penalty will not cause the non-solicitation clause to terminate and will not exclude the Company from applying other statutory relief, including injunction. 

 

	13.4	 To the extent the Company obtains penalties and/or damages under this clause 13, the Company shall not be
entitled to obtain penalties and/or damages in respect of the same loss/breach under the shareholders’ agreement regarding the Company to which the CEO is a party with regard to the same subject matter. 

 

	14	 Insurance & Limitation of liability 

 

	14.1	 The Company undertakes to take out and maintain a D&O insurance program (in Danish
“ledelsesansvarsforsikring”) providing a cover of at least DKK 5,000,000 per event per year and a cover for litigation costs of at least DKK 1,250,000 per year per event, as well as any mandatory insurance programs such as a
Workmans Compensations program (In Danish “arbejdsskadeforsikring”). 

  

	14.2	 In case of the CEO becoming liable to the Company under this Service Agreement for losses incurred related to
the CEO’s employment with the Company, the Company must primarily seek compensation from the insurance programme taken out as per clause 14.1 above and only upon exhaustion thereof seek compensation from the CEO. Liquidated

  
 5 

	 	
damages pursuant to clauses 12.6 and 13.3 shall only be incurred if the CEO does not remedy the breach alleged within 10 calendar days from having been notified about an alleged breach. The
accumulated liabilities of the CEO, including both losses incurred and liquidated damages, for any breach of this agreement shall in no event exceed DKK 500,000. 

 

	14.3	 The DKK 500,000 cap of the CEO’s liability set out in clause 14.2 shall not apply in the case of gross
negligence or wilful misconduct by the CEO. Furthermore, for the avoidance of doubt, the Company is under no obligation to hold the CEO harmless for any loss incurred by any third party which such third party pursuant to applicable law is entitled
to claim from the CEO. 

  

	15	 Intellectual property rights 

 

	15.1	 Ownership in and any right of exploitation to inventions, methods,
know-how, patents, trademarks, texts, computer programmes, pictures, illustrations, drawings, designs, models, prototypes. formula, graphic images, concepts and other intellectual property rights (jointly
referred to as “Rights”) that the CEO has developed, may develop or may participate in developing (whether alone or jointly with others) during the term of her employment in the course of the rendering of services under this agreement
shall be conferred upon the Company without separate remuneration as the CEO’s salary and other terms provided for in this Service Agreement constitute due compensation in this respect. The same shall apply to any such Rights that the CEO may
develop or participate in developing within one year after the termination of the employment. 

  

	15.2	 The Rights are conferred upon the Company regardless of whether the Rights fall within the scope of the
Company’s activities, whether the Rights were achieved outside normal working hours, or whether the Rights were developed at the Company’s premises or elsewhere. 

 

	15.3	 The CEO must immediately inform the Company in the event that Rights have been or can be expected to be fully
or partly developed by the CEO. 

  

	15.4	 The CEO undertakes to provide the Company with every reasonable assistance in protecting, using and improving
its Rights, including – but not limited to – signing all declarations, documents and permits and disclose all such information that the Company may regard as necessary or desirable for the purpose of (i) transferring, registering or
obtaining the Rights in the name of the Company, and (ii) ensuring that the Company can obtain patent, utility, design, copyright or trademark protection anywhere in the world. A rejection (explicit or by
non-corporation) by the CEO to comply in any material respect with this clause 15.4 shall be considered a material breach of this Service Agreement. 

 

	15.5	 The transfer to the Company of copyrights in copyright protected material, products, etc. (jointly referred to
as the “Material”) confers upon the Company an exclusive right to use the Material indefinitely in any way and in any form, all over the world and without restrictions. Moreover, the Company is entitled to make changes to the Material and
to transfer fully or partly the copyright to others. The Parties have agreed that sections 54 and 55 of the Danish Act on Copyright shall not apply; hence the CEO cannot cancel the transfer of the copyright due to the Company’s failure of
exploitation, and equally the transfer of the copyright for unspecified kinds of exploitation cannot be terminated. 

  
 6 

	16	 Information security 

 

	16.1	 The CEO is obliged in every respect to observe the Company’s general and specific directions on
information security, including directions concerning use of e-mail and internet. Failure to observe these directions may have consequences for the CEO’s employment. 

 

	16.2	 To the extent the Board of Directors deems it necessary in consideration of the security or the operations of
the Company – the CEO hereby consents to registration and reading of the CEO’s e-mails and control of the CEO’s use of the internet by a representative of the Company. 

 

	17	 Termination 

  

	17.1	 The CEO’s employment may be terminated by the Company with six months’ written notice effective to
the end of a month and by the CEO with three months’ written notice effective to the end of a month. 

  

	17.2	 If the Company or the CEO commits a material breach of the obligations of this Service Agreement, the other
party is entitled to terminate the Agreement without notice. 

  

	18	 Miscellaneous 

 

	18.1	 The CEO shall inform the Company of the CEO’s current private address. 

 

	18.2	 The CEO is not considered a salaried employee of the Company. Accordingly, the CEO is not covered by the Danish
Salaried Employees Act, the Danish Holiday Act or other legislation protecting the interests of employees. 

  

	18.3	 The Company is in the process of preparing procedures and documents to comply with the Data Protection
Regulation which will enter into force in May 2018. In connection with such procedures, all employees of the Company, including the CEO, will receive a separate addendum to their employment agreement concerning the processing of personal data to
comply with the Data Protection Regulation. 

  
 7 

	19	 Choice of law and venue 

 

	19.1	 This Service Agreement is governed by and construed in accordance with Danish law. 

 

	19.2	 Any dispute concerning this Service Agreement shall be settled exclusively by the ordinary Danish courts.

 This Service Agreement is signed in two identical copies, of which each party receives one. 

 

					
	On behalf of the Company:	 		 	On behalf of the CEO:
			
	Date: _____ March 2018	 		 	Date: _____ March 2018
			
	/s/ Peter Hirth	 		 	/s/ Mai-Britt Zocca
	Peter Hirth, Chairman	 		 	Mai-Britt Zocca

  

	
	
	/s/ Claus Asbjarn Anderson
	Claus Asbjarn Anderson, board member

  
 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]